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8ABSTRACT
Background and aims
Patients with end-stage renal disease and on chronic renal replacement therapy are 
at increased risk of death compared to a population of the same age without end-
stage renal disease. Despite some improvement in prognosis of end-stage renal 
disease patients during recent decades, the expected outcome remains dismal. 
Several factors are associated with impaired survival of patients with end-stage 
renal	disease:	especially	high	age,	 low	serum	albumin,	chronic	 inflammation,	
and comorbidities such as diabetes and heart failure. However, a major portion 
of	factors	behind	impaired	survival	have	been	insufficiently	identified,	and	their	
prognostic weight is largely unknown. We therefore targeted for further exploration 
and measurement of factors potentially associated with survival of patients on 
chronic renal replacement therapy.
Study patients and methods
In the four studies of this thesis, we investigated the survival of cohorts of adult 
patients in Finland after the start of chronic renal replacement therapy. These 
cohorts were in Study I, 1,604 patients with type 1 diabetes and 1,556 with 
glomerulonephritis who started chronic RRT during 1980–2005; in Study II, 
319 patients during one year (1998) preceding start of chronic renal replacement 
therapy and thereafter; in Study III, all 4,463 patients who started chronic renal 
replacement therapy in 2000–2009; in Study IV, all 6,103 patients who entered 
chronic dialysis in 2000–2012.
Data on patient cohorts came from the Finnish Registry for Kidney Diseases, 
a database including comprehensive information on Finnish patients on chronic 
renal replacement therapy since 1964. In Study III, data also came from the 
Finnish Kidney Transplant Registry.
The statistical methods mainly employed in our survival analyses were Kaplan-
Meier curves, the log rank test, and Cox proportional hazards regression and 
binary logistic regression for multivariable modeling. 
Results
In Study I, we showed that survival of patients with type 1 diabetes receiving 
chronic	renal	replacement	therapy	has	 improved	significantly	and	consistently	
over the years and in all age-groups. Patients entering chronic renal replacement 
therapy in 2000–2005 had a 77% lower risk of death than those entering in 1980–
1984. Said another way, median survival time of patients with type 1 diabetes on 
chronic renal replacement therapy has increased from 3.6 years to more than eight.
9In	Study	II,	we	detected	a	significantly	higher	age-adjusted	mortality	in	those	
on chronic renal replacement therapy whose decline in estimated glomerular 
filtration	rate	during	the	predialysis	phase	had	been	the	fastest.	Their	mortality	risk	
was 73% higher in the patient tertile of fastest decliners compared to the slowest. 
This association, however, proved not to be causal, but instead jointly caused by 
many confounding factors, especially age, end-stage renal disease diagnoses type 1 
diabetes and amyloidosis, and the comorbidities myocardial infarction and cancer.
In Study III, results of our primary adjusted analyses (intention-to-treat) 
indicated	no	significant	difference	in	risk	of	death	between	patients	on	chronic	
renal replacement therapy who started with peritoneal dialysis compared to those 
who started with hemodialysis. Without adjustment, the relative risk of death of 
peritoneal dialysis patients was 0.65 (95% CI 0.58-0.73, p<0.001) compared to 
hemodialysis patients. With adjustment for 26 potentially confounding variables, 
the corresponding relative risk was, however, 1.07 (95% CI 0.94-1.22, p=0.33). 
Results from our secondary analysis method (as-treated) and further with full 
adjustment, however, indicated a 17 to 33% higher relative risk of death for 
patients exclusively treated by peritoneal dialysis compared to those treated by 
hemodialysis exclusively.
In Study IV, we developed one- and two-year all-cause mortality prediction 
models for patients starting chronic dialysis. These models were based on a less-
recent training cohort and validated with a more recent validation cohort. As a 
result, area under the curve for the one-year model (with seven variables) reached 
0.77 and for the two-year model (with six variables) 0.74. Because mortality in the 
more	recent	patient	cohort	was	significantly	lower	than	in	the	less-recent	cohort,	
both models slightly overestimated mortality risk.
Conclusions
Based on studies described in this thesis, survival of Finnish patients with type 1 
diabetes	and	end-stage	renal	disease	has	significantly	improved	since	the	beginning	
of the 1980s, despite their conspicuous increase in age, and has improved relatively 
more in patients with type 1 diabetes than in patients with glomerulonephritis, 
suggesting progress both in dialysis therapy and overall management of patients 
with end-stage renal disease and, quite evidently, also in management of diabetes. 
Furthermore,	factors	behind	the	rapid	decline	in	estimated	glomerular	filtration	
rate during the year preceding the start of chronic renal replacement therapy, 
and effects of these factors on subsequent survival are now better characterized. 
Rate	of	decline	in	estimated	glomerular	filtration	rate	is	not	a	causal	factor	for	
survival, but instead a marker of other factors associated with end-stage renal 
disease patients’ survival. In addition, based on this research, no overall difference 
appeared in survival regarding modality of dialysis. Patients starting chronic 
dialysis	 differ	 significantly	 between	dialysis	modalities	with	 respect	 to	many	
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patient-level prognostic factors, but after comprehensive adjustment for these 
putative confounders, no survival advantage of one dialysis modality over another 
emerged. And lastly, important factors affecting one- and two-year mortality of 
Finnish	patients	starting	chronic	dialysis	are	now	identified	and	their	prognostic	
weight	can	be	investigated.	Based	on	these	findings,	we	constructed	two	models	
for survival estimation hopefully to be implemented in individualized treatment-
planning of patients approaching chronic renal replacement therapy.
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ABSTRACT IN FINNISH
Tutkimuksen taustaa ja tavoitteet
Loppuvaiheen munuaisten vajaatoiminnan aktiivihoidossa olevia potilaita hoi-
detaan munuaisten korvaushoidolla eli dialyysillä tai heillä on toimiva munuais-
siirrännäinen. Vaikka näiden potilaiden eloonjäämisennuste on kohentunut 
 jonkin verran viime vuosikymmenien aikana, heidän kuolleisuutensa on edelleen 
merkitsevästi suurempi kuin saman ikäisellä, munuaisiltaan terveellä väestöllä. 
Ennustetta heikentävät erityisesti korkea ikä, matala seerumin albumiinipitoisuus, 
krooninen tulehdustila ja liitännäissairaudet kuten diabetes ja sydämen vajaa-
toiminta. Ennustetekijöitä on toistaiseksi kuitenkin tunnistettu vajavaisesti, ja 
tekijöiden ennusteellinen merkitys on epäselvä. Tämän väitöskirjatyön tavoitteena 
oli tunnistaa loppuvaiheen munuaisten vajaatoimintaa sairastavien potilaiden 
eloonjäämisennusteeseen vaikuttavia tekijöitä ja arvioida niiden painoarvoa.
Tutkimuspotilaat ja –menetelmät
Väitöskirjan neljässä osatyössä tutkimme eloonjäämistä neljässä, pitkäaikaisen 
munuaisten korvaushoidon aloittaneen aikuispotilaan ryhmässä. Osatyöhön 
I valittiin Suomen kaikki ne tyypin 1 diabetesta (yhteensä 1604) ja munuais-
kerästulehdusta (yhteensä 1556) sairastavat potilaat, jotka aloittivat munuaisten 
korvaushoidon vuosina 1980–2005. Osatyössä II tutkittiin munuaisten korvaus-
hoidon vuonna 1998 aloittaneita potilaita (yhteensä 319). Osatyöhön III otettiin 
mukaan kaikki 4463 vuosina 2000–2009 ja osatyöhön IV kaikki 6103 vuosina 
2000–2012 dialyysin Suomessa aloittaneet potilaat.
Potilasryhmien tiedot saatiin Suomen munuaistautirekisteristä, joka sisältää 
kattavaa ja monipuolista tietoa Suomessa pitkäaikaisen munuaisten korvaus-
hoidon aloittaneista potilaista vuodesta 1964 lähtien. Osatyössä III käytimme 
myös tietoja, jotka saimme HYKS:n munuaisensiirtoyksikön valtakunnallisesta 
seurantarekisteristä.
Tärkeimmät käyttämämme tilastolliset menetelmät olivat Kaplanin-Meierin 
menetelmä, log rank -testi ja Coxin suhteellisten riskitiheyksien regressio sekä 
monen selittäjän binaarinen logistinen regressio.
Tulokset
Osatyössä I osoitimme, että tyypin 1 diabetesta sairastavien, pitkäaikaisessa mu-
nuaisten korvaushoidossa olevien potilaiden eloonjäämisennuste on parantunut 
merkitsevästi viimeisten vuosikymmenien aikana. Ennuste on parantunut kaikissa 
ikäryhmissä. Vuosina 2000–2005 pitkäaikaiseen munuaisten korvaushoitoon 
tulleiden kuolemanriski oli 77% pienempi kuin vuosina 1980–1984 hoidon aloit-
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taneilla. Eloonjäämisajan keskiluku munuaisten korvaushoidossa nousi samassa 
ajassa 3,6:sta vuodesta yli 8:an vuoteen.
Osatyössä II totesimme, että ikävakioitu kuolemanriski oli merkitsevästi suu-
rempi niillä pitkäaikaisessa munuaisten korvaushoidossa olevilla potilailla, joi-
den laskennallinen munuaiskerässuodoksen laskunopeus dialyysiä edeltävässä 
ns. predialyysivaiheessa oli ollut nopein. Kuolemanriski oli 73% suurempi, kun 
verrattiin laskennallisen munuaiskerässuodoksen laskun osalta nopeinta potilas-
kolmannesta hitaimpaan kolmannekseen. Kyseessä ei kuitenkaan ollut syy-seu-
raussuhde munuaiskerässuodoksen laskunopeuden ja kuolemanriskin välillä, 
vaan kuolemanriskin erilaisuus johtui useasta sekoittavasta tekijästä, kuten ikä, 
munuaisten vajaatoiminnan aiheuttanut sairaus (tyypin 1 diabetes ja amyloidoosi) 
ja sellaiset liitännäissairaudet kuten sydäninfarkti ja syöpä.
Osatyössä III verrattiin kuolemanriskiä pitkäaikaisen vatsakalvodialyysin 
ja hemodialyysin aloittaneiden potilaiden välillä. Vakioidussa pääanalyysissä 
(intention-to-treat) ei ilmennyt eroa kuolemanriskissä. Ilman vakiointia 
vatsakalvodialyysin aloittaneiden suhteellinen kuolemanriski oli 0,65 (95% CI 
0,58-0,73, p<0.001) verrattuna hemodialyysin aloittaneisiin. Kun kuolemanriski 
vakioitiin 26:lla mahdollisella sekoittavalla tekijällä, niin vastaava suhteellinen 
kuolemanriski oli 1,07 (95% CI 0,94-1,22, p=0.33). Toissijaisena käyttämämme, 
täysin vakioitu analyysitapa (as-treated) osoitti 17-33% korkeampaa kuolemanriskiä 
yksinomaan vatsakalvodialyysissä olleilla potilailla verrattuna pelkästään 
hemodialyysillä hoidettuihin potilaisiin.
Osatyössä IV kehitimme yksi- ja kaksivuotiskuolemanriskiä ennustavat mal-
lit. Mallien rakentaminen suoritettiin pitkäaikaisen munuaisten korvaushoidon 
vuosina 2000–2008 aloittaneiden potilaiden tietojen pohjalta, ja mallit validoi-
tiin (vahvistettiin) uudemmalla potilasryhmällä (vuosina 2009–2012 hoidon 
aloittaneet). Mallien kyky ennustaa yksilöllistä kuolemanriskiä (area under the 
curve, AUC) oli yksivuotismallilla (seitsemän muuttujaa) 0,77 ja kaksivuotismal-
lilla (kuusi muuttujaa) 0,74. Molemmat mallit yliarvioivat kuolemanriskiä jonkin 
verran johtuen validointiryhmän merkitsevästi vähäisemmästä kuolleisuudesta 
verrattuna ryhmään, jonka tiedoilla mallit rakennettiin.
Päätelmät
Tämän väitöskirjatyön osatöiden perusteella voidaan sanoa seuraavaa: 1)  Tyypin 
1 diabetesta sairastavien suomalaisten, pitkäaikaisessa munuaisten korvaus-
hoidossa olevien potilaiden eloonjääminen on parantunut merkitsevästi vuo-
desta 1980 lähtien. Eloonjäämisennuste on parantunut siitäkin huolimatta, että 
munuaisten korvaushoidon aloittavat potilaat ovat vuosi vuodelta iäkkäämpiä. 
Ennuste on kohentunut tyypin 1 diabeetikoilla suhteellisesti enemmän kuin 
munuaiskeräs tulehdusta sairastavilla potilailla viitaten kehitykseen sekä munu-
aisten korvaus hoitojen tekniikoissa ja pitkäaikaisessa korvaushoidossa olevien 
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hoidossa ylipäätään, että varsin selvästi myös kehitykseen diabeteksen hoidossa. 
2) Predialyysivaiheen laskennallisen munuaiskerässuodoksen laskunopeuteen 
vaikuttavat tekijät on nyt tunnistettu aiempaa tarkemmin ja arvioitu näiden te-
kijöiden liittyminen eloonjäämisennusteeseen pitkäaikaisessa munuaisten kor-
vaushoidossa. Laskennallisen munuaiskerässuodoksen laskunopeus predialyysi-
vaiheessa ei ole suoraan kuolemanriskiin vaikuttava tekijä, vaan osoitin muista, 
kuolleisuuteen liittyvistä tekijöistä. 3) Eloonjäämisennusteessa ei ole eroa vatsa-
kalvo- ja hemodialyysin aloittavien potilaiden välillä Suomessa. Näihin kahteen 
dialyysin päämuotoon valikoituvat potilaat ovat hyvin erilaisia monien ennus-
teeseen liittyvien tekijöiden suhteen. Kun suoritetaan kattava vakiointi näiden 
mahdollisesti sekoittavien tekijöiden suhteen, ei voida todeta eroa eloonjäämi-
sennusteessa dialyysihoitomuotojen välillä. 4) Pitkäaikaisen dialyysin aloittavien 
potilaiden eloonjäämisen yksi- ja kaksivuotisennusteeseen vaikuttavat tekijät on 
nyt kartoitettu Suomessa. Näiden tekijöiden avulla on muodostettu mallit, jotka 
toivotaan otettavan käyttöön arvioitaessa pitkäaikaista dialyysihoitoa aloittavien 
potilaiden yksilöllistä eloonjäämisennustetta.
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1 INTRODUCTION
The	number	of	patients	with	severe	renal	insufficiency	and	also	the	number	on	
chronic renal replacement therapy (RRT) is increasing (1-3). In Finland, this is 
mainly due to the general ageing of the population, a high incidence of type 1 
diabetes, and a growing incidence of type 2 diabetes (1). As the population with 
severe	renal	insufficiency	is	expanding,	and	especially	as	patients	on	chronic	RRT	
live longer, the number of patients remaining on programs for chronic RRT is 
increasing (1).
End-stage renal disease (ESRD) raises mortality risk many-fold compared to 
those without ESRD (4, 5). The risk is further heightened with increasing age (6) 
and in the presence of comorbidities such as heart failure (7-9) and comorbid 
conditions such as hypoalbuminemia (10). Certain causes of ESRD such as type 
2 diabetes are also associated with impaired survival (11). Of all patients starting 
chronic dialysis, approximately 71% are alive after two years but only 48% after 
five	years	(12).	Although	survival	of	some	patient	groups	on	RRT	has	improved,	in	
general the outcome of patients on chronic RRT is dismal (13, 14). Furthermore, in 
addition to diabetes, other comorbidities have become more frequent among ESRD 
patients (7). Nevertheless, progress taken place in many areas of nephrological 
care (such as diabetic nephropathy), and RRT techniques (like dialysis dose and 
delivery), have already translated in many ESRD populations into improved 
prognosis (1, 15, 16).
The growing number of patients with ESRD also create growing demands on 
nephrological health care, not to mention the increased individual morbidity and 
mortality burden upon these patients (17, 18). To tackle these major obstacles, 
researchers have attempted to clarify factors associated with increased mortality of 
ESRD patients. Identifying these factors linked to poor outcome could be helpful 
in many ways: in 1) improving ESRD management, 2) targeting more sound use 
of nephrological health care resources, and most importantly 3) improving ESRD 
patients’ survival and quality of life.
An important and large ESRD patient group in Finland is the one with type 
1 diabetes (1). Risk of patients with type 1 diabetes to develop ESRD decreased 
during recent past decades (19). Furthermore, according to some studies, the 
mortality of patients with type 1 diabetes on chronic RRT also seems to have 
decreased (20-22). Overall, however, data on prognosis have been very limited.
The decision on when to start chronic RRT is in most cases set individually 
and based on information including patient’s uremic symptoms, laboratory test 
results	(level	of	renal	insufficiency),	and	availability	of	RRT	resources	(23,	24).	
During the predialysis phase (i.e., time-period before start of chronic RRT) patients 
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with chronic kidney disease (CKD) are regularly monitored for uremic symptoms 
and	kidney	 function.	A	common	method	 to	assess	 level	of	 renal	 insufficiency	
is	estimation	of	glomerular	filtration	rate	(GFR)	(25).	The	pace	at	which	renal	
function deteriorates is individual: some are followed by nephrologists for years 
with only gradually decreasing estimated GFR (eGFR) before entering chronic 
RRT, while some others present with quickly worsening renal function and thus 
quicker RRT initiation. Many investigators have tried to discover the optimal level 
of eGFR at start of chronic RRT with regard to subsequent mortality on RRT, 
resulting in opposite estimations with respect to general expectations (26-34). 
However, no earlier published data exist on the association between predialysis 
phase change in eGFR and subsequent survival on chronic RRT.
When the start of chronic RRT approaches, the decision needs to be: which 
dialysis modality (i.e., hemodialysis, HD or peritoneal dialysis, PD) will be started. 
And further, which modality would be the most suitable for that individual patient 
(17, 35-37), and, would the dialysis modalities differ with respect to mortality? 
Several studies have focused on association of dialysis modality with survival 
on	 chronic	RRT	 (38-56).	Results	have	been	 either	 conflicting	or	 showing	no	
superiority	of	one	modality	over	another.	No	Finnish	data	in	the	field	have	existed	
before	our	findings.
In addition to these factors related to outcome, many other co-existing 
factors are associated with survival of chronic RRT patients (6, 7, 10, 57-61). 
Their	identification	and	knowing	their	prognostic	weight	would	enable	us	to	build	
models for individual risk-assessment (62-70), to help 1) teach nephrologists ESRD 
management and individualized treatment-planning, 2) give patients insight into 
decisions concerning their treatment, and 3) the nephrological health care system 
as a whole in delivering limited resources fairly and equally.
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2 REVIEW OF THE LITERATURE
2.1 END-STAGE RENAL DISEASE
ESRD is the term for a situation in which renal clearance of uremic toxins has 
fallen	 to	be	so	 low	that	 the	sequel,	 irreversible	severe	renal	 insufficiency	with	
uremic	symptoms	(fatigue,	nausea,	body	fluid	retention,	pruritus,	etc.),	warrants	
chronic RRT.
2.1.1 INCIDENCE, PREVALENCE, ETIOLOGY
Between	countries	and	populations,	the	incidence	of	ESRD	(defined	as	start	of	
chronic RRT) varies greatly. In 2012 the incidence was the highest in the world in 
Taiwan and in Jalisco (Mexico), with 467 and 450 new patients entering chronic 
RRT per million population (pmp) (71). In contrast, the number of ESRD patients 
in some European countries is among the lowest in the world, approximately 110 
to 140 pmp per year in the majority of them, and approximately 130 pmp in the 
whole of Europe in 2013 (2). In Finland, where ESRD incidence is the lowest 
among the Nordic countries, an increase occurred for decades to approximately 
500 (ca. 100 pmp) new patients annually. This may have resulted from the growing 
number with prior hypertension or type 2 diabetes, and of elderly patients accepted 
for active treatment programs (1). Recently, however, growth in incidence has 
diminished in Finland, especially among the elderly, reaching a plateau in 2004, 
after which there have been about 450 new cases of ESRD annually (72). In 2013, 
485 new patients entered chronic RRT (89 pmp) in Finland, with approximately 
two-thirds of them males (1). Because the Finnish population is aging rapidly, 
ESRD incidence is expected to rise again in the coming years (15).
As	 to	 the	 prevalence	 of	 ESRD	 (defined	 as	 chronic	 RRT),	 it	 also	 varies	
significantly	between	populations,	from	Taiwan’s	about	2,900	prevalent	ESRD	
patients	pmp	(71),	and	Europe’s	(as	a	whole)	corresponding	figure	of	950	pmp	
(2),	to	Finland’s	internationally	low	figure	of	about	800	pmp	(1).	By	the	end	of	
2013 in Finland, ESRD prevalence was 24% higher than in 2003 and 7% higher 
than in 2008 (1). The prevalence of chronic RRT patients is increasing in most 
countries because the number of patients entering chronic RRT exceeds that of 
patients leaving chronic RRT. Several factors relate to this: 1) in many countries, 
an	increasing	number	of	patients	with	severe	renal	insufficiency	are	offered	chronic	
RRT; 2) patients on chronic dialysis live longer on dialysis; 3) the number of 
patients receiving a kidney transplant is increasing; and 4) the prognosis of patients 
with a kidney transplant is improving (1, 2, 72-74). In Finland in 2013, the number 
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of patient-years on chronic RRT was 4,464, of which 2,652 (59%) in patients with 
a functioning kidney transplant, 1,464 (33%) in patients on HD, and 348 (8%) 
in patients on PD (1).
Typical diseases causing ESRD have included type 1 and 2 diabetes, 
glomerulonephritis, nephrosclerosis, polycystic kidney disease, pyelonephritis, and 
amyloidosis. In 2013 in Finland, based on patient-years on chronic RRT, 16% had 
type 1 diabetes as the cause of ESRD, 10% type 2 diabetes, 22% glomerulonephritis, 
4% nephrosclerosis, 14% polycystic kidney disease, and 6% pyelonephritis (1). 
The number with type 2 diabetes entering chronic RRT grew substantially until 
2002 and has then stabilized. The number of patients with glomerulonephritis 
or polycystic kidney disease has been stable even longer, and ESRD prevalence 
caused	by	amyloidosis	has	significantly	decreased.
2.1.2 GLOMERULAR FILTRATION RATE
The	 term	GFR	describes	 the	 volume	 of	 plasma	 filtrated	 through	 the	 renal	
glomeruli	 per	 unit	 of	 time.	 Some	molecules	 are	 freely	 filtered	 through	 the	
kidneys,	but	for	most	molecules,	the	filtration	coefficient	is	less	than	one	(75).	
The unit used is ml/min or ml/s per 1.73 m2 body surface, and, excluding 
possible renal reabsorption and tubular excretion, it approximates the clearance 
of the molecule from plasma by the kidneys. In clinical practice, the estimation of 
clearance of creatinine is the most commonly used method to assess a patient’s 
renal	“purification”	capability	and	therefore	to	detect	possible	renal	insufficiency.
2.1.2.1  Estimation
The gold standard for measuring GFR is measurement of clearance of Cr-
EDTA (chrome-ethylenediaminetetraacetic acid). This chrome-labeled isotope 
is	 given	 intravenously	 and,	 subsequently,	 during	 the	 following	 five	 hours	
repeatedly measured from blood (76). The test is laborious and expensive, and 
for the patient rather troublesome. Thus, for practical purposes GFR is usually 
calculated with mathematical formulas approximating the value of true GFR, 
by producing estimated GFR (eGFR). For creatinine clearance, several formulas 
exist: for instance, the Cockcroft-Gault formula, the various forms of MDRD 
(Modification	 for	Diet	 in	Renal	Disease)	 formulas,	and	the	CKD-EPI	(Chronic	
Kidney Disease Epidemiology Collaboration) formula (25, 77-79). They differ in 
possessing somewhat different measurement accuracy depending on degree of 
renal	insufficiency	(25,	79,	80).
In the studies included here, choice of the MDRD formula was based on its 
better	measurement	capability	(reliability)	in	severe	renal	insufficiency	compared	
to that of the older Cockcroft-Gault equation (77). For this reason, we favored 
the MDRD formula in the follow-up especially of predialysis patients (77, 81). Of 
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note, the newer CKD-EPI formula, presently used was not yet widely used when 
these studies were performed. The MDRD formula used herein was:
eGFR (MDRD) = 175 x (plasma creatinine in µmol/L/88.4)-1.154 x age-0.203 for 
males. Equation is multiplied by 0.742 for females (77).
CKD	is	staged	depending	on	degree	of	chronic	renal	insufficiency	(Table	1)	(82).
Table 1  Chronic kidney disease (CKD) staging and corresponding values of glomerular 
filtration rate (GFR).
CKD stage Degree of renal insufficiency GFR, ml/min
1 Normal >90
2 Mild 60-89
3A
Moderate
45-59
3B 30-44
4 Severe 15-29
5 ESRD <15 or on dialysis
All GFR values are normalized to an average surface area (size) of 1.73 m2
2.1.2.2  Factors associated with rapid eGFR decline
Investigators have found factors associated with rapid deterioration of renal 
function, even to the stage of ESRD (83, 84). Decline in eGFR is especially 
rapid in acute severe nephrological diseases, including rapidly progressing 
glomerulonephritis and vasculitis, and acute kidney injury in certain poisonings 
(85-87). Often this is the case also in patients with acute kidney injury imposed 
on	pre-existing	chronic	renal	 insufficiency	(88).	In	a	more	chronic	setting,	the	
diseases causing ESRD vary in their typical eGFR decline pattern; for instance, 
patients with type 2 diabetes usually have a more rapid decline than do patients 
with primary renal disorders such as polycystic disease or pyelonephritis (89, 
90).	 Some	 other	 non-specific,	 comorbid	 characteristics	 are	 associated	 with	
accelerated rate of eGFR decline. Albuminuria, hematuria, high age, male gender, 
low serum albumin, high serum phosphate, metabolic acidosis, hyperlipidemia, 
anemia, certain comorbidities (hypertension, left ventricular hypertrophy) and late 
nephrology referral have been associated with enhanced CKD progression during 
the	predialysis	phase	(84,	91-93).	Identification	of	risk	factors	for	progression	of	
CKD to ESRD could provide potential targets for preventive interventions (83, 
94). However, despite efforts to discover factors affecting the rate at which renal 
function declines, progressing to ESRD, our knowledge of rapid eGFR decline 
is limited.
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2.1.2.3  Pattern of eGFR decline and mortality
At the time of starting maintenance (chronic) RRT, patients present with stage 
5 CKD (eGFR < 15 ml/min/1.73 m2). The patterns and speeds at which patients 
enter chronic RRT, however, differ greatly. In the acute setting, the approach is 
often rapid and may last only from days to weeks, whereas patients with gradually 
worsening	chronic	renal	 insufficiency	often	approach	chronic	RRT	with	rather	
steadily declining eGFR and over a period of up to several years (91).
The pace at which eGFR declines and its subsequent effect on mortality has 
been the topic of several investigations (95-98). Rifkin and colleagues investigated 
creatinine and serum cystatin C in an elderly cohort of 4,380 patients with mild 
renal	insufficiency	(i.e.,	not	yet	with	predialysis	phase	insufficiency),	in	which	a	
yearly eGFR decline over 3 ml/min/1.73 m2 was associated with an increased 
risk for cardiovascular and all-cause mortality (95). Wu and colleagues followed 
573 CKD 3-5 patients for 12 months to investigate the effect of multidisciplinary 
predialysis patient education on risk for developing ESRD or dying, and found 
that the patients who had received enhanced training had a slower eGFR decline 
and, furthermore, were at decreased risk of death during the predialysis phase 
and had a decreased need to enter chronic RRT (96). Survival on chronic RRT 
was not analyzed.
In a more recent study, Chen and colleagues found that predialysis patients 
with early nephrological referral (over six months before start of chronic RRT) 
showed better survival than did those patients with later referral (97). Survival in 
this cohort was analyzed from an estimated time-point at which eGFR was below 
15 ml/min/1.73 m2. In all these studies, survival was analyzed for patients with 
varying CKD stages, with none of the studies extending to assess mortality after 
chronic	RRT	start.	Importantly,	no	prior	studies	report	specifically	the	effect	of	
pace of eGFR decline during the predialysis phase on subsequent survival when 
on chronic RRT.
2.1.2.4  eGFR at RRT start and mortality
Knowledge of predialysis factors affecting outcome on RRT is limited; the same 
can be said about our knowledge of the optimal timing of start of chronic RRT 
with regard to survival when on chronic RRT. It was generally believed that early 
RRT start (i.e., at higher eGFR) is important for patients’ well-being and connected 
to better outcome (99, 100). This was based on observational or retrospective 
studies with potential bias related to patient selection, laboratory methods, or 
lead-time in dialysis initiation (99, 101). The opposite emerged later, when many 
observational studies paradoxically showed that survival of patients starting RRT 
at lower eGFR values was better than (29, 102) or no different (103) from that 
of starters with higher eGFR. However, in the only randomized controlled trial 
comparing early to late dialysis start, no survival difference appeared (104). In 
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that trial, patients were randomly assigned to 1) start dialysis when eGFR was 
10-14 ml/min/1.73 m2 (early-start group, n=404) or 2) to continue with routine 
care until eGFR reached 5-7 ml/min/1.73 m2, at which point dialysis was started 
(late-start group, n=424). During the follow-up (median 3.6 years) 152 patients 
in the early-start group and 155 patients in the late-start group died, with no 
significant	difference	in	survival	(hazard	ratio	for	death	in	the	early-start	group	
1.04;	95%	confidence	 interval,	0.83-1.30,	p=0.75).	Of	note,	however,	 the	 true	
difference between the study groups in mean eGFR (MDRD) value at RRT start 
was rather small (9.0 versus 7.2 ml/min/1.73 m2), and as many as 76% of the 
patients in the late-start group started RRT with eGFR over 7 ml/min/1.73 m2.
2.2 CHRONIC RENAL REPLACEMENT THERAPY
Chronic RRT is started when a patient presents with ESRD, and renal clearance 
of uremic toxins has diminished to a level causing uremic symptoms, which 
usually happens when GFR decreases to less than 10 ml/min/1.73 m2 (100). The 
start of chronic RRT is usually preceded by a so-called predialysis phase, during 
which the patient is closely and regularly monitored by a nephrological unit to 
give	individualized	treatment	for	uremia	and	to	detect	and	respond	to	findings	
(symptoms, laboratory test results) necessitating start of RRT (100).
2.2.1 MODALITIES
The three main modalities of chronic RRT are HD, PD, and kidney transplantation 
(105). The two main forms of dialysis, HD and PD, are technically unique and 
different from each other, and both include several subforms. In the third chronic 
RRT modality, kidney transplantation, a functioning kidney is transplanted.
2.2.1.1  Hemodialysis
HD	is	a	RRT	technique	in	which	a	patient’s	blood	is	directed	through	a	specific	filter	
(hemodialyzer,	hemofilter)	containing	very	small,	hollow-fiber	capillaries	(106).	
The membrane walls of the capillaries contain microscopically small pores making 
the capillaries semipermeable and thus capable of allowing some (especially; small) 
molecules to pass from the blood circulation to the outside of the capillaries and 
into	the	dialysis	fluid.	The	dialysis	fluid	flows	in	the	hemodialyzer,	outside	of	the	
capillaries and in the opposite direction to that of the blood. Access to a patient’s 
blood is obtained via 1) a two-lumen catheter inserted into a central vein enabling 
blood to be both drawn in and returned simultaneously, or 2) via an arteriovenous 
fistula	or	an	artificial	arteriovenous	graft	in	which	two	dialysis	needles	are	placed.	
If	there	is	no	pressure	gradient	between	the	blood	and	dialysis	fluid,	the	technique	
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uses pure diffusion (osmosis) to transport the molecules of higher concentration 
in	the	blood	to	the	lower	concentration	in	dialysis	fluid	(106).	HD	is	especially	
effective for removing small (molecular weight < 500 Dalton), water-soluble, non-
protein-bound uremic toxins (e.g., urea, potassium, phosphorus) from the blood, 
and depending on dialyzer and the size of its capillary pores, this technique is 
variably effective also for removing molecules of larger molecular weight (e.g., beta-
2-microglobulin, immunoglobulin light chain, molecular weight 500 to 60,000 
Dalton). The effectiveness of toxin clearance by the dialyzer also depends on the 
area	of	its	capillaries’	surface,	and,	on	rates	of	blood	and	dialysis	fluid	flow.
When	a	pressure	gradient	 is	 applied	 to	 the	dialyzer,	 and	no	dialysis	fluid	
is used, the technique used is called convection (107). With this technique 
(isolated	ultrafiltration),	plasma	water	may	be	removed	from	a	patient,	aiming	
at	diminishing	fluid	overload.	However,	along	with	removed	plasma	water,	small,	
clinically non-relevant amounts of uremic toxins also shift from the blood to 
dialysis	fluid,	but	only	at	a	concentration	in	which	they	are	diluted	in	the	blood,	
and thus this technique does not effectively clean a patient’s blood of uremic 
toxins. Diffusion and convection techniques can also be combined, in which case 
simultaneous	HD	is	done	at	 the	same	time	with	removing	excess	fluid	 from	a	
patient (108).
Hemofiltration	 implies	 a	 technique	 in	which	 the	amount	of	ultrafiltration	
exceeds	the	amount	of	fluid	removal	desired	for	a	patient,	and	thus	replacement	
fluid	(also	called	filtration	fluid)	must	be	infused	into	a	patient’s	blood	to	maintain	
hemodynamic	stability	and	targeted	fluid	balance	(109).	The	replacement	fluid	
is infused either before or after the hemodialyzer (pre- or postdilution), with 
simultaneous	removal	of	at	least	the	same	amount	of	fluid	in	the	dialyzer.	This	
technique mainly uses convection, but also exerts its clearance with diluting and 
correcting	concentration	of	uremic	 toxins	 in	 the	blood	by	 the	specific	content	
of	 the	filtration	fluid.	For	 instance,	 if	potassium	concentration	 in	 the	blood	 is	
6	mmol/L,	and	the	concentration	in	the	filtration	fluid	is	2	mmol/L,	the	blood	
concentration of potassium is inevitably and gradually reduced by the infusion 
of	filtration	fluid.	Consequently,	when	removing	a	corresponding	amount	of	the	
diluted	plasma	water	in	the	dialyzer,	uremic	toxins	may	be	purified	from	a	patient.	
The	clearance	of	toxins	by	hemofiltration	depends	mostly	on	the	rate	of	filtration	
fluid	infused	and	removed	(109).
When diffusion and convection techniques are combined, the technique is 
called	hemodiafiltration	(HDF),	with	enhanced	clearance	of	solutes	 in	a	wide	
spectrum of molecular weights compared to purely diffusive HD (108, 110). 
There are several forms of HDF modality, including high-volume HDF and 
online	HDF,	with	either	pre-	or	postdilution	 infusion	of	filtration	fluid	 (110).	
HDF is a newer technique than HD, and its use is gradually increasing along 
improvements accomplished in dialyzer development and technology allowing 
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use	of	large	amounts	of	ultrapure	online	filtration	and	dialysis	fluids.	HDF	offers	
higher clearance of uremic toxins than HD, and there are data suggesting increased 
survival in patients treated with online HDF (50, 108). With the additive clearance 
effect	of	filtration	fluid	(aka.,	replacement	fluid)	used	in	HDF,	the	clearance	is	
further	 increased	by	 the	so-called	high-flux	dialyzers,	with	a	highly	permeable	
membrane	and	larger	membrane	area	compared	to	low-flux	dialyzers,	which	are	
still the mainstream in HD (106). Another advantage of HDF is associated with 
the better hemodynamic tolerance it carries for some patients (108, 111). This 
effect, however, is probably mainly caused by enhanced cooling of blood in HDF 
compared to standard HD (108, 112). In Finland, about 21% of all chronic HD 
patients receive HDF (74).
2.2.1.2  Peritoneal dialysis
PD is a RRT modality in which removal of uremic waste products takes place 
by diffusion in the peritoneal cavity, across the peritoneal membrane from the 
underlying	capillaries	 into	PD	fluid	(113).	Excess	plasma	water	passes	 into	PD	
fluid	caused	by	the	relative	hyperosmolality	of	PD	fluid.	The	PD	fluid	(also	called	
dialysate) is infused into a patient’s peritoneal cavity through a permanent silicon 
rubber tube (PD catheter), which is inserted either laparoscopically or with open 
(surgical) placement and extends from the cutaneous surface and through the 
abdominal muscles to lower parts of peritoneal cavity (114). After an individually 
suitable	dwelling	time	(usually	a	few	hours),	during	which	uremic	toxins	and	fluid	
are	transported	into	PD	fluid,	the	fluid	(i.e.,	dwell)	is	drained	out	of	the	peritoneal	
cavity	through	the	same	one-lumen	PD	catheter.	After	that,	fresh	fluid	is	again	
infused into the peritoneal cavity for about 10 to 15 minutes’ time, and a new cycle 
of	PD	treatment	is	started.	PD	fluid	typically	consists	of,	in	addition	to	sodium,	
chloride and bicarbonate, a high percentage of glucose to create hyperosmolality, 
which	 is	responsible	 for	the	ability	of	PD	fluid	to	remove	excess	plasma	water	
from	the	blood	circulation	(115).	Usually	 the	 total	volume	of	 infused	PD	fluid	
used	at	one	time	is	1500	to	2500	mL.	The	volume	of	outflow	fluid	depends	on	
how	much	extra	removed	fluid	accompanies	the	dialysate,	and	how	much	of	the	
dialysate is absorbed (116).
There are several forms of PD. Internationally the most popular one is 
continuous	 ambulatory	 PD	 (CAPD)	 (2),	 in	 which	 fresh	 PD	 fluid	 is	 infused	
approximately	every	four	to	six	hours,	and	typically	four	to	five	times	a	day	(usually	
with a longer dwelling time during the night) (114). CAPD is, however, a rather 
laborious and time-consuming technique which usually requires the patient to 
be	at	home	at	regular	times	of	drainage	and	infusion	of	new	fluid.	Due	to	this,	
automated PD (APD) has gained increasing popularity, allowing treatment-free 
day-time	while	a	PD	machine	performs	 the	fluid	exchanges	during	 the	night	
with the patient asleep (117, 118). The drawback of APD compared to CAPD is, 
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however, its considerably higher cost. Overall, most forms of PD treatment can 
be considered advantageous over in-center HD in that they can be performed at 
home and thus without the patient needing often to visit a nephrological unit (119).
On PD, clearance of uremic toxins mainly depends on the intensity of PD 
treatment and characteristics of the peritoneum (113). In general, depending on 
the	individual’s	particular	peritoneal	characteristics,	PD	is	intensified	by	either	
an	increase	in	number	of	fluid	exchanges	or	an	increase	in	dwelling	time,	and	by	
use	of	PD	fluids	containing	higher	concentrations	of	glucose.	Characteristics	of	
the peritoneum between individual patients vary greatly; whereas the transport 
of	toxins	and	exchange	of	fluids	in	some	patients	occur	rapidly,	in	some	others	it	
takes longer, and patients’ peritoneal characteristics must be taken into account 
in individualized management of PD (113).
2.2.1.3  Kidney transplantation
In kidney transplantation, a functioning kidney is transplanted either from a 
deceased or a living donor. The transplant is placed underneath the abdominal 
skin and muscles in the extraperitoneal space, on the anterior side of the abdomen, 
either right or left. Depending on many factors, the transplant may already start 
functioning during the operation or soon after the transplantation, or it may exhibit 
delayed graft function, and sometimes, although fortunately not often, will never 
function. As both recipients and donors have become older during recent years, 
the incidence of delayed graft function has increased (failure of serum creatinine 
level	to	decrease	by	10%	on	three	consecutive	days	during	the	first	postoperative	
week) (120). Already approximately 50% of the recipients experience late onset 
for the graft to function (121).
Of all chronic RRT modalities, kidney transplantation can be considered the 
one best resembling and replacing the earlier native kidney which ceased to 
function, and therefore also the most physiological modality of chronic RRTs 
(122). Although immunosuppressant therapy and many other medications 
are mandatory after transplantation, the use of, for instance, erythropoiesis-
stimulating agents, phosphate-lowering agents, and agents for treating secondary 
hyperparathyroidism	 may	 in	 many	 cases	 be	 significantly	 reduced	 or	 even	
discontinued (123, 124). A well-functioning kidney transplant also restores and 
maintains	a	normal	fluid	homeostasis	and	partly	helps	to	ensure	normal	blood	
pressure (125). Arterial hypertension is, however, approximately equally prevalent 
in transplanted patients, as is use of antihypertensive medication in patients on 
chronic HD (74, 126).
The outcome of patients who have received a kidney transplant is as such 
considerably better than the outcome of HD or PD patients, but no randomized 
controlled trials have objectively compared kidney transplantation to dialysis 
treatments. Of all chronic RRT patients, the ones selected to receive a kidney 
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transplant are in general younger and with fewer comorbidities than the ones 
who never receive a kidney transplant, and also possess other characteristics 
associated with favorable prognosis (127, 128).
2.2.2 SELECTION OF DIALYSIS MODALITY
The selection of a patient’s modality of chronic RRT requires thorough evaluation 
of both advantages and disadvantages, and the decision is affected by many 
factors, both treatment- and patient-related (129). Examples of patient-related 
factors include urgency of RRT start, the patient’s overall physical and mental 
state, severity of possible comorbidities, and socio-economic and occupational 
conditions (23). In addition, considerations on availability of local health care 
resources and varying experience in using different modalities are important.
RRT modalities which encourage maintaining the patient’s personal way of 
living	and	quality	of	life	can	be	seen	as	the	first	choices	in	helping	to	preserve	the	
patient’s autonomy and thus minimally disabling the patient, preventing him/her 
from living the kind of life he/she desires (119). On the other hand, modalities like 
CAPD, APD, and home-HD require independent initiative as well as the patient’s 
adopting and learning the modalities, and are therefore not applicable for all 
patients. While APD or home-HD often offer freedom from daytime dialysis and 
better suit relatively healthy patients still active in working life, in-center HD is 
often the only option for many of the patients, and especially for those with the 
most physical disability. 
Selection of the RRT modality to be preferred varies greatly across the world 
especially due to uneven distribution of local resources and differences that 
modality causes in clinical practice (71). Furthermore, varying geographical 
circumstances may be important to take into consideration. In a setting where it 
is urgent to start chronic RRT, the modality chosen for the vast majority of patients 
is HD, due to its rather straight-forward approach and the relative technical ease 
with regard to its start and usually the excellent availability of the technique. When 
initiation of chronic RRT can be planned without any major hurry, there is a better 
chance to consider the suitability of other modalities. In these circumstances, PD 
is quite often the modality of choice. Whereas PD treatment may be suitable for up 
to 75% of patients starting chronic RRT, the actual incidence is much lower. The 
most common reasons are contraindications to PD (like prior major abdominal 
operations) and especially patients’ views of acceptable dialysis modality (130, 131). 
Worldwide	distribution	of	HD	and	PD	varies	significantly	between	countries,	from	
97% in HD and 3% in PD in Japan, to 27% and 73% in Hong Kong (71). Although 
RRT	modalities	which	support	patient	autonomy	are	usually	considered	the	first	
option to offer to those capable of performing them, in a study exploring worldwide 
use of different RRT modalities in 2004, only approximately 11% of chronic RRT 
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patients were receiving PD, and only 0.4% home-HD (132). In geographically large 
countries with proportionally few nephrological centers in their vast rural areas, 
PD is, however, often an attractive home-dialysis modality. In many countries, 
kidney transplantation is quite commonly performed instead of any dialysis, but 
in countries like Finland, pre-emptive kidney transplantation is rather rare.
In most European countries and on day 91 after start of chronic dialysis 
treatment, the dialysis modality of those patients starting RRT in 2011 was some 
form of HD in 71 to 84% (65-110 pmp), PD in 10 to 20% (15-25 pmp) and kidney 
transplantation	in	1	to	6%	(4-10	pmp)	of	the	patients,	with	significant	variability	
between countries, especially for the two latter modalities (2). In 2013 in Finland, 
among 485 patients, the RRT modality by which chronic treatment was started 
was HD in 350 (72%), PD in 134 (28%) and pre-emptive kidney transplantation 
in one (1). In 2012, of all the Finnish PD patients, approximately 42% used CAPD 
and 58% APD (74).
2.3 SURVIVAL ON CHRONIC RENAL REPLACEMENT   
 THERAPY
2.3.1 FACTORS ASSOCIATED WITH INCREASED MORTALITY
In patients on chronic RRT, various patient-level properties are related to survival. 
Such properties are many, and the most important has very commonly been patient 
age (6). Other factors often strongly associated with survival are serum albumin 
and certain comorbidities such as heart failure, cancer, and chronic infection/
inflammation	(9,	10,	61,	133,	134).	For	patients	entering	chronic	RRT,	the	etiology	
of ESRD may also be a strong predictor of impaired survival; this applies, for 
instance, to type 2 diabetes and amyloidosis (11, 20, 135, 136).
Patient characteristics, their relation to survival, and comparison of survival 
between various patient groups are typically assessed in observational follow-up 
studies. In order to perform reliable survival analyses, it is vitally important to 
account for all possible effects on mortality of numerous patient- and treatment-
related factors. This is especially important when comparing patient groups that 
differ with regard to frequency of the characteristics (61). Failing to perform 
comprehensive adjustment of these putative confounding factors will lead to false 
results (137).
2.3.2 PATIENTS WITH TYPE 1 DIABETES
Diabetes mellitus (types 1 and 2 combined) is the most important cause of ESRD 
in industrialized countries (2). In Finland, incidence of type 1 diabetes is among 
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the highest in the world (138). Great progress has occurred, however, in treatment 
of type 1 diabetes since the 1970s, with many forms of improved insulin regimens 
and	intensified	blood	glucose	monitoring,	resulting	in	fewer	episodes	of	hypo-	and	
hyperglycemia, and closer-to-target blood glucose levels (139). Overall, all these 
improvements have diminished the frequency of diabetic nephropathy and of 
ESRD due to diabetic kidney disease (140). Moreover, the risk of Finnish patients 
with type 1 diabetes to develop ESRD has been diminishing over the past four to 
five	decades	(19).	Whether	progresses	in	overall	management	of	type	1	diabetes	
could	also	reflect	improved	survival	on	chronic	RRT	is	still	largely	unknown.
Survival of Danish patients with diabetes (types 1 and 2 combined) (21) and 
Finnish patients with type 2 diabetes (136) on chronic RRT has improved during 
recent	decades.	Furthermore,	survival	of	patients	with	specifically	type	1	diabetes	
as	the	etiology	of	ESRD	has	probably	also	improved	(20,	141).	However,	conflicting	
results have also been published, showing no improvement in survival of this 
patient group (22). 
Recently, in Finnish ESRD patients with type 1 diabetes, certain comorbidities 
(for instance, heart failure and peripheral vascular disease), have been associated 
with increased mortality (8). In addition, a higher number of comorbidities in 
these patients is correlated with higher risk of death (8). Study of the long-term 
survival of Finnish patients with type 1 diabetes on RRT has been neglected.
2.3.3 DIALYSIS MODALITY AND SURVIVAL
For decades, nephrologists have puzzled over the question whether either of the 
main dialysis modalities is superior to the other with regard to survival in chronic 
use (142).
HD and PD techniques differ so much that these techniques per se could be 
expected to cause survival difference. We know that the frequency of adverse events 
between dialysis modalities differs, and this could alter patient survival (142, 143). 
On HD, on the one hand there are non-infectious complications relating to catheter 
insertion (144), and on the other, inadequate sterility in treatment procedures 
causing a higher risk for catheter-related septicemia and other infections (145). In 
addition, on HD hypotension and potentially hazardous electrolyte disturbances 
are rather frequent (146). On PD, risk for peritonitis related to the treatment is 
clearly elevated, with about 0.03 to 0.20 episodes per patient-year depending on 
the microorganism (147, 148). Furthermore, almost constant exposure to glucose-
containing	PD	fluids	and	loss	of	plasma	albumin	into	PD	fluids	are	subjects	of	
concern (143, 149).
Survival on chronic dialysis is associated with the years spent on dialysis 
treatment, with increasing risk with longer duration on dialysis, but the difference 
in death risk between dialysis modalities seems not to be linear (39, 41, 43-45). 
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According	to	others’	results,	mortality	risk	is	lower	during	the	first	one	to	two	years	
on PD, but after that, the risk would equal that on HD (39, 40). Furthermore, 
according to some investigators, the risk is elevated in those patients who change 
their initial dialysis modality (39, 42).
Many patient characteristics are associated with survival. Of such character-
istics, especially age, serum albumin, and certain comorbidities (such as heart 
failure) have been strong prognostic factors (8, 58, 150). In patients on chronic 
RRT, many of the same characteristics are related to survival as in the non-ESRD 
population (150). In addition, comorbidities such as ischemic heart disease and 
cardiac left ventricular hypertrophy (9, 133, 134), and causes of ESRD such as type 
2 diabetes and amyloidosis (11, 135, 136, 151) are portents of increased mortality 
risk on RRT. The magnitude of risk associated with a comorbidity also seems to 
vary according to dialysis modality (38-41, 152). The death risk caused by heart 
failure is higher on HD than on PD (9, 133). PD, on the other hand, has seemed 
to pose a lower risk in young patients without comorbidities (39, 40) and a higher 
risk in older patients with diabetes (41, 47). On the other hand, for non-diabetic 
patients, no survival difference is apparent between continuous ambulatory PD 
and HD (46).
Survival on chronic RRT is also likely to depend on whether a patient has 
received a kidney transplant (153). To take this into account in survival analyses is 
complex, however, as the frequency of transplantations is very different between 
HD and PD patients (15, 154, 155); comparison between these patient groups would 
therefore require either a randomized study setting or otherwise an exceptionally 
good balance in patient characteristics.
To date, only one randomized study has compared survival of patients on 
chronic dialysis between HD and PD (156). That study was prematurely halted 
because	too	few	patients	were	recruited,	and	it	failed	to	achieve	sufficient	statistical	
power.	All	the	other	studies	published	in	the	field	have	been	observational	and	
showed	either	conflicting	results	or	no	significant	superiority	of	one	modality	over	
another (38-56). Thus, there still has been no conclusive answer to whether any 
survival advantage results from either main dialysis modality when used as the 
first-line	chronic	dialysis	therapy.
2.3.4 PRE-ESTIMATION OF MORTALITY RISK
A large number of registries collect information on chronic patients and 
their illnesses. The quality of registry data is critical: the more accurate and 
comprehensive the data, the more reliable the study results based on them. 
Importantly, it is crucial for the data to include the most important factors relating 
to the outcome under investigation. In Finland, the Registry for Kidney Diseases 
has an exceptionally complete coverage of Finnish nephrological units and ESRD 
patients who have entered chronic RRT (1).
28
Patient- and treatment-related factors associated with patient survival have 
been used in constructing mathematical formulae to estimate individual mortality 
risk (137). These formulae are mathematical algorithms which allow incorporation 
of a minimal number of factors, each of which contributes independent predictive 
information. These algorithms can then serve as models to estimate patient-level 
mortality risk.
One	 of	 the	 first	 and	 most	 often	 applied	 models	 has	 been	 the	 Charlson	
Comorbidity	Index	(157),	and	for	ESRD	patients	its	modified	version	(158).	Many	
similar tools, also ones taking into account factors other than comorbidities, have 
been constructed by several research teams in various countries (62-70). These 
tools were in most cases based on administrative or registry data derived from 
incident ESRD populations. A typical method to design a model has been to select 
a cohort of ESRD patients who have recently entered chronic RRT (typically 
within three months) and to calculate predictive probabilities of various patient 
characteristics by choosing the ones most relevant to the population investigated 
(137). Following this, a cohort is typically divided into two: a training group used 
only for model development, and an internal validation group used only for 
assessing the predictive ability of the model.
This predictive ability depends on two main properties: its performance in 
calibration (usually assessed by the Hosmer-Lemeshow test) and discrimination 
(often assessed by a c-statistic, area under the receiver operating characteristic 
curve	 [AUC]).	 In	 final	 prediction	models,	 especially	 the	 latter	 performance	
(AUC) has been widely employed (137). A c-statistic (AUC) of 0.5 would mean 
no predictive ability of the model, and an AUC of 1.0, perfect predictive ability. 
Most studies reach an AUC between 0.72 and 0.84 for one-year prediction of death 
risk and an AUC between 0.67 and 0.75 for two-year prediction. An AUC value of 
0.75	has	been	considered	sufficient	by	the	majority	(64-70,	159,	160).	Performance	
in calibration can be done by comparing average predicted probabilities of death 
to	observed	mortality,	sometimes	shown	graphically	in	articles.	A	non-significant	
P value in the Hosmer-Lemeshow test would indicate good calibration, that is, 
good resemblance between predicted and observed mortality.
In a study by Mauri and coworkers, 5,738 incident Catalonian HD patients 
from 1997 to 2003 were randomly divided into development (60%) and validation 
(40%) groups (64). The investigators build a one-year predictive model with 
10 variables and reached an AUC of 0.78. Another study focusing on one-year 
mortality after start of chronic RRT was by Quinn and colleagues who investigated 
16,025 incident Canadian dialysis patients (HD 76%, PD 24%) from 1998 to 2005 
(67). With diverse statistical methods, they built a predictive model with an AUC 
of 0.76 and a summary risk score including data on socioeconomic status and 
a	wide	range	of	comorbidities.	The	final	mortality	prediction	model	comprised	
15 variables; it may in that respect be less convenient for everyday clinical work.
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Other large studies have aimed at longer than one-year prognostication. Liu and 
colleagues investigated very large incident and prevalent US dialysis populations 
(over 240,000 in total, the proportions of HD/PD not reported) from 1999 to 
2001, with a follow-up reaching 2.5 years (66). By inclusion of data on 11 comorbid 
illnesses, they developed a comorbidity score. The performance of the model 
exceeded that of the earlier Charlson Comorbidity Index, but discrimination could 
still only reach an AUC of 0.67. The quality of that study has been questioned 
based on possible weaknesses in data sources and its including only patients who 
survived for over nine months on RRT. The model was also developed to predict 
length and number of hospitalizations and help in medical cost analyses and was 
reported to perform well for these tasks. A three-year model was built by Wagner 
and colleagues using data from an incident UK dialysis population of 5,447 (HD 
approx. 70%, PD approx. 30%) during 2002–2004 (68). A validation cohort of 
1,816 was internal, but almost half of the original incident patients were excluded 
due to missing data. This model was able to differentiate patients in four levels 
of mortality risk (low – intermediate – high – very high) with an AUC of 0.73 in 
the validation group.
Another model aiming at long-term prognostication was developed by Hemke 
and colleagues using Dutch registry data on 13,868 patients who entered RRT 
from 1995 to 2005 (69). Their 10-year model performed similarly to the models 
described above (AUC 0.72), and they used internal validation. In addition to 
these studies done at a national level, a multinational study based on ERA-EDTA 
Registry involving 793 centers from 37 countries (including a total of 2,310 
patients) created two novel prognostic models (63). Their models performed 
better	in	longer	(five-year)	than	shorter	(one-year)	prediction.
30
3 AIMS OF THE STUDY
The main aim of this study was to investigate factors associated with mortality of 
patients on chronic RRT. In more detail, we targeted the following aims:
1. To investigate whether survival of patients with type 1 diabetes has improved 
since 1980, and to which factors any possible change could be attributed (I)
2. To explore the association between eGFR decline patterns and long-term 
survival of all patients entering chronic RRT by using multiple predialysis 
measurements of serum creatinine to calculate eGFR slope (II)
3. To investigate the association between dialysis treatment modality and 
survival on chronic RRT (i.e., to compare patients starting with HD to those 
starting with PD), and to learn whether this association varies between major 
subgroups of patients (III)
4. After analyzing which factors are the most important for survival of patients 
on chronic RRT, to use this information to construct a mathematical risk-
stratification	model	to	estimate	patient	survival	on	chronic	RRT	(IV)
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4 SUBJECTS AND METHODS
4.1 DATA SOURCE
Data on subjects of all the studies in the thesis came from the Finnish Registry 
for Kidney Diseases, a national registry recording information on all patients 
entering chronic RRT in Finland since 1965 (1). This registry is maintained by the 
Finnish	Kidney	and	Liver	Association	and	financed	by	the	Finnish	government.
Data of the registry are provided directly by the Finnish nephrological care-
providers, the treating nephrologists, and the units delivering nephrological care; 
data and patient coverage of the registry is therefore considered exceptionally 
reliable. This information is collected on regular basis and includes data on 
demographics (age and gender), date of RRT start, modality of RRT, comorbidities, 
medication,	and	results	of	pre-defined	 laboratory	 tests.	 Importantly,	extensive	
data were collected in 1998 on, for instance, development of serum creatinine 
values before patients’ entering chronic RRT, and, since 2000, comprehensively 
on comorbidities at start of RRT. Renal disease diagnoses have earlier been stored 
as	International	Classification	of	Diseases	(ICD)	-9	codes	and	more	recently	as	
ICD-10 codes. All patients entering chronic RRT provide written informed consent 
and permission to use the data anonymously in registry reports and for research 
purposes. Thus, no additional approval of any ethics committees was required 
for the observational studies of the thesis.
In Study III, we also used data retrieved from the Finnish Kidney Transplant 
Registry, which is maintained by the Kidney Transplantation Unit of Helsinki 
University Hospital. This registry includes comprehensive information on 
waitlisted and transplanted patients.
Table 2  Subjects of the four studies included in the thesis.
Study I Study II Study III Study IV
Patients (n) 3,160 319 4,463 6,103
Time period  
of entrance 
to chronic RRT, 
years
1980−2005 1998 2000−2009
Training group: 
2000−2008 
Validation group: 
2009−2012
Follow-up until 31 Dec 2007
31 Dec 
2008 31 Dec 2009
Training group: 
1 or 2 years after 
the start of dialysis
Validation group:  
31 Dec 2013
Age, years All ≥ 20 ≥ 20 ≥ 18
RRT, renal replacement therapy
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4.2 SUBJECTS AND DESIGNS OF THE FOUR STUDIES
4.2.1 STUDY I
In Study I, we investigated factors affecting survival of patients with type 1 
diabetes on chronic RRT. We included an incident cohort of all 1,604 patients 
with type 1 diabetes and all 1,556 with glomerulonephritis as the cause of ESRD 
who had entered chronic RRT from 1 January 1980 to 31 December 2005 (Table 
2).	They	were	followed	from	the	first	day	of	RRT	until	death	or	the	end	of	follow-
up on 31 December 2007, or until recovery of kidney function, or until they 
had moved abroad or were lost to follow-up (Table 3). We used the cohort with 
glomerulonephritis as a control group to represent primary renal disease to allow 
us to perform a comparison between the impact of RRT-associated factors and 
the impact of factors associated with diabetes care.
Table 3  Baseline characteristics of the patient populations in Studies I-IV.
Study I Study II Study III Study IV
Patients, n 1,604
1
1,5562 319 4,463
4,335 (training group) 
1,768 (validation group)
Median age at RRT start, 
years
41.01
53.12 60.0 62.4
62.3 (training)
64.1 (validation)
Males, % 63.8
1
71.82 60.3 63.8
63.5 (training)
67.8 (validation)
Median follow-up, years 5.2 6.0 2.8 N.A.
Maximum follow-up, years 28 11 10 2
Died during follow-up, n 1,047
1
8232 214 1,887
1 year: 597
2 years: 1,080
Censored patients, n 557
1
7332 243 2,576
1 year: 3,738
2 years: 3,255
    Alive at end of follow-up 548
1
7192 235 2,494
1 year: 3,674
2 years: 3,172
    Regained kidney function 5
1
82 8 78
1 year: 63
2 years: 81
    Loss to follow-up 0
1
22 0 1
1 year: 0
2 years: 1
    Moved abroad 4
1
42 0 3
1 year: 1
2 years: 1
RRT, renal replacement therapy
1Patients with type 1 diabetes
2Patients with glomerulonephritis
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During this time-period, a total of 8,719 patients started chronic RRT, 
and of these the ESRD cause was for 18.4% type 1 diabetes and for 17.8% 
glomerulonephritis.	The	ESRD	diagnosis	was	confirmed	by	kidney	biopsy	in	80	
(5%) patients with type 1 diabetes and 980 (63%) with glomerulonephritis. In the 
glomerulonephritis group, the frequency of kidney biopsies clearly increased over 
the years, reaching 73 to 85% during 1995–2005, whereas in the type 1 diabetes 
group, the frequency remained low. It has been, and still is, a widely accepted 
practice not to perform kidney biopsies in patients with type 1 diabetes if they 
show, in addition to nephropathy, also signs of other microvascular end-organ 
damage, such as diabetic retinopathy.
In addition to comparing the two main ESRD groups, we divided the patients 
into four age-groups based on age at start of RRT: under 35 (444 patients), from 
35 to 44 (586), from 45 to 54 (383) and 55 or over (191). Furthermore, we divided 
the	study	period	into	five	intervals:	1980–1984,	1985–1989,	1990–1994,	1995–
1999, and 2000–2005.
4.2.2 STUDY II
Study II was designed to investigate patterns of eGFR slope before entering 
chronic RRT and related survival subsequently on RRT. For that aim we studied 
all incident patients 20 years or older having started chronic RRT from 1 January 
1998 to 31 December 1998 (Table 2). These patients were followed from their 
first	day	of	dialysis	until	death	or	the	end	of	follow-up	on	31	December	2008,	or	
until recovery of kidney function, or until the patients had moved abroad or were 
lost to follow-up (Table 3).
These patients were grouped into tertiles according to eGFR slope, which 
was based on three creatinine measurements preceding commencement of RRT; 
those 107 patients with the most rapid decline (over 8.5 ml/min/1.73 m2/year), 
the intermediate group of 107 (decline 3.4-8.5 ml/min/1.73 m2/year), and the 105 
patients with the slowest decline (less than 3.4 ml/min/1.73 m2/year). These data 
were	derived	from	a	specific	questionnaire	asked	to	be	filled	out	for	each	of	the	
457 new patients entering chronic RRT in 1998 in Finland. The questionnaire 
went to all nephrologists who treated these patients and surveyed comprehensive 
information	including	data	on	specific	laboratory	results,	among	which	were	values	
for serum creatinine during the 12 months prior to RRT start. Of the total 457 
patients,	the	questionnaire	was	sufficiently	completed	for	94%,	and	of	these,	those	
eight	who	regained	kidney	function	and	those	23	who	died	within	the	first	three	
months were excluded.
We used data on serum creatinine measured at three time-points: approximately 
12 months, three months and one to two weeks prior to start of chronic RRT. 
Completeness of data on creatinine increased towards the start of RRT: for 329, 
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356, and 365 patients at those three time-points. At all the three time-points, we 
had data on the 319 patients (70% of those who initially entered RRT) who were 
finally	included	in	the	study.
For	estimation	of	GFR,	we	used	 the	Modification	of	Diet	 in	Renal	Disease	
(MDRD) formula (eGFR = 175 x [plasma creatinine in µmol/L/88.4]-1.154 x age-
0.203 for males, and this equation multiplied by 0.742 for females) (161). In order 
to calculate the slope of eGFR for each patient, we applied a linear regression 
formula:	(eGFR	=	a	+	β	x	T).	In	the	formula	“a”	represented	eGFR	at	start	of	RRT,	
“β”	(beta)	stood	for	slope,	and	“T”	the	time	(in	years)	from	the	first	creatinine	
measurement to start of RRT. As a result, we were able to obtain annual eGFR 
slopes (in ml/min/1.73 m2), based on which the abovementioned patient grouping 
was then done.
4.2.3 STUDY III
Study III compared survival of chronic RRT patients according to initial dialysis 
modality, that is, HD versus PD. The time-point of chronic RRT was set to 91 days 
after	the	first	dialysis	treatment,	as	by	that	time	(approximately	three	months)	
the intended chronic dialysis modality has usually been established. Our study 
population was a cohort consisting of all 4,754 patients 20 years or older who 
started chronic RRT from 1 January 2000 to 31 December 2009 (Table 2). Of 
these, we excluded 291 patients for these reasons: 137 had died before 91 days on 
RRT, for 15 their dialysis treatment had been discontinued, eight had regained 
their kidney function, 37 had received a kidney transplant before 91 days on 
RRT, and 94 had been less than 91 days on dialysis before the end of follow-up. 
Subsequently,	4,463	were	 included	 in	 the	final	analyses.	These	patients	were	
followed	from	the	day	of	first	dialysis	treatment	until	death,	recovery	of	kidney	
function, moving abroad, loss to follow-up, or end of the follow-up period on 31 
December 2009 (Table 3).
We used two designs of approach in grouping the patients: 1) an intention-
to-treat approach (primary analysis), in which we divided the patients into two 
groups (HD or PD) according to their dialysis modality on day 91, and 2) an as-
treated approach (secondary analysis), in which the patients were divided into 
four groups according to dialysis modality on day 91, and additionally, whether 
they stayed permanently in that initial modality until kidney transplantation or 
end of follow-up, or if they changed to the other dialysis modality. Accordingly, 
the established four modality groups were 1) those exclusively on HD, 2) those 
exclusively on PD, 3) those who changed from HD to PD, and 4) those who 
changed from PD to HD. This grouping allowed us a comparison of patients who 
had been exclusively on PD to those who had been exclusively on HD.
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In both approaches, the HD group included in-center HD for 3,122 and HDF 
for 19, and home-HD for 105; the PD group comprised patients with any form 
of PD treatment (667 on continuous ambulatory PD, 535 on automated PD, and 
15 on intermittent PD).
Due to the very different frequencies between HD and PD patients of 
transplant waitlisting and transplantations performed, and to address the potential 
confounding effect of these differences, we adjusted for kidney transplant waitlist 
status at three months from RRT start. We also censored at the time of kidney 
transplantation, but only as an additional analysis approach. Furthermore, as 
an alternative to censoring, we performed adjustment for transplantation as a 
time-dependent variable, resulting in a very similar outcome to that of censoring 
at transplantation.
4.2.4 STUDY IV
In Study IV, we aimed to construct mathematical algorithms for prediction of 
one- and two-year all-cause mortality of patients starting chronic RRT. These 
algorithms would include the most important factors associated with survival, and 
be chosen based on analyses of data from the Finnish Registry for Kidney Diseases.
In order to construct the two prediction models (one- and two-year mortality), 
we chose a training and a validation group. The former consisted of all 4,341 
incident patients 18 years or older who entered chronic RRT from 1 January 
2000 to 31 December 2008, from among whom we removed the six patients with 
pre-emptive kidney transplantation (Table 2). Of note, we did not include any 
patients	who	were	able	to	withdraw	from	dialysis	during	the	first	three	months	
on dialysis, because they were not considered as chronic RRT patients. These 
4,335	patients	were	followed	from	the	first	day	of	dialysis	until	death	within	one	
or two years, until recovery of kidney function after three months from RRT 
start, or moving abroad, loss to follow-up, or end of follow-up period (Table 3). 
The validation group comprised all 1,770 patients 18 years or older who entered 
chronic RRT from 1 January 2009 to 31 December 2012, namely coming from a 
later period than the training group; this enabled us to have an external cohort 
exclusively	used	for	validation	of	the	final	models.	The	two	patients	having	had	
transplantation	as	their	first	RRT	modality	were	excluded.	We	followed	survival	
of these patients until 31 December 2013. We therefore could perform follow-up 
of one-year survival for the whole validation group, but of two-year survival only 
for those 1,341 who started dialysis at the latest on 31 December 2011.
On the basis of the literature, clinical expertise, and data availability in the 
Registry, we selected a large number, 32, of variables as candidates to be tested 
for their predictive performance (see list in Table 1 of the Study IV original 
publication). Data were unavailable to varying degrees depending on the variable 
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in	question,	and	of	the	variables	chosen	for	the	final	models	were	as	follows:	age	
at RRT start 0%, ESRD diagnosis 0%, albumin 4%, phosphorus 3%, C-reactive 
protein 20%, heart failure 9%, peripheral vascular disease 6%, and peripheral 
vascular disease with limb amputation 7%.
4.3 STATISTICAL ANALYSES
Comparisons between groups were performed with the chi-square test for 
categorical variables and the Mann-Whitney U- or Kruskal-Wallis test for 
continuous variables. We calculated survival probabilities with the Kaplan-Meier 
method, with death as the event, and patients were censored according to study-
specific	inclusion	and	exclusion	criteria.	Median	survival	times	were	estimated	
from the Kaplan-Meier curves, and differences in survival probabilities between 
groups were assessed by the log rank test. We used Cox proportional hazards 
regression to perform multivariable modeling of survival probabilities. When 
studying comorbidities in multivariable analysis, we used the assumption that 
missing data equals absence of comorbidity (Study II). In Study III, we employed 
both intention-to-treat and as-treated analysis methods. Furthermore, in Study 
III, we tested proportional hazards assumptions in the multivariable Cox model 
by calculating Schoenfeld residuals according to dialysis modality and correlating 
these	with	 time	of	 follow-up.	A	non-significant	correlation	 indicated	 that	 the	
proportional hazards assumptions were not violated. Proportionality of hazards 
was also evaluated by studying the interaction of dialysis modality and time 
of follow-up. Two-sided p-values lower than 0.05 were considered statistically 
significant	and	lower	than	0.001	highly	significant.	All	first-	and	second-degree	
interactions between the explanatory variables considered relevant to the results 
were tested in the Cox model-building (Study II). In Study III, to avoid type I 
error due to multiple testing, a two-sided p-value lower than 0.01 was considered 
statistically	 significant	 in	 the	 interaction	analyses.	Due	 to	missing	data	 in	 the	
original Registry database, and in order to have no biased analysis results because 
of exclusion of a large number of patients, we performed multiple imputation for 
missing data (in Studies III and IV) in which the explanatory variables (and not 
the	outcome	variable)	served	to	impute	missing	values.	The	final	multivariable	
model	was	pooled	from	five	imputed	datasets.
In Study IV, prediction algorithms were developed with use of multivariable 
logistic regression with the binary outcome of death or not within one or two 
years	 from	 start	 of	 RRT.	 The	Hosmer-Lemeshow	 (goodness-of-fit)	 test	 was	
used to assess calibration and the c-statistic (AUC) for discrimination. To detect 
non-linearity between continuous predictors and the outcome, we categorized 
continuous variables into three to six groups and modeled the categorical variables 
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in	univariate	 logistic	regression	analysis.	 If	we	observed	non-linearity,	we	first	
evaluated logarithmic transformation of the predictor and then compared it to 
no transformation and the categorical variable. Subsequently, we calculated 
predicted probabilities and constructed graphs for continuous variables against 
probability	of	mortality,	 followed	by	 choosing	 the	best-fitting	 transformation	
(either linear, logarithmic, or group variable) according to the -2 Log likelihood- 
and the Hosmer-Lemeshow test. We calculated the predicted probabilities with 
the following equation:
Predicted probability = 1 / (1 + e-logit), where e is the base of the natural logarithm 
2.71828,	and	logit	is	defined	as:
logit	=	β0	+	β1χ1	+	β2χ2	+	βmχm,	where	β0	 is	 the	constant	of	 the	 logistic	
regression	equation,	and	β1	to	βm	represent	regression	coefficients	of	the	variables	
χ1	to	χm.
The	regression	coefficients	can	be	calculated	by	taking	the	natural	logarithm	
of the odds ratios for survival probability. With this equation, it is possible to 
calculate predicted probability of death for each patient.
Further, in Study IV, we used forward and backward stepwise procedures to 
select the variables among the 32 original ones with the strongest effect on survival. 
After interim analyses, only variables with a p-value of 0.05 or lower were taken 
to the next step (leaving 15 in the one-year model and 13 in the two-year model), 
followed by another assessment in a logistic regression model, after which (in 
order	of	statistical	significance)	variables	were	further	evaluated	in	4-15	variable	
combinations. These combinations were compared for predictive performance 
(discrimination	and	calibration)	within	the	training	group.	The	final	predictive	
models	contained	only	highly	significant	(p<0.001)	variables:	seven	in	the	one-
year model and six in the two-year model.
For statistical analyses we used SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) 
and versions 18 and 20 (IBM Inc., Armonk, NY, USA) and Stata 12 (StataCorp LP, 
College	Station,	TX,	USA).	All	possible	first-degree	(Studies	I	to	IV)	and	second-
degree (Studies I and II) interactions between the explanatory variables were 
considered in the building of the multivariable regression models.
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5 RESULTS
Table	3	describes	baseline	characteristics	of	the	final	patient	populations	included	
in the four (I-IV) studies (Table 3).
5.1 SURVIVAL OF PATIENTS WITH TYPE 1 DIABETES  
 RECEIVING RENAL REPLACEMENT THERAPY  
 IN 1980–2007
Many changes in characteristics of patients with type 1 diabetes entering chronic 
RRT have taken place. Median age at initiation of RRT increased from 34.8 years 
in 1980–1984 to 44.6 years in 2000–2005 (p<0.001). The proportion of PD 
as	 the	first	RRT	modality	 decreased	 from	55%	 to	48%.	Frequency	 of	 kidney	
transplantation performed within two years from RRT start diminished to 35% 
in 2000–2005, whereas it was 60% in 1980–1984.
5.1.1 CRUDE SURVIVAL
During follow-up, of the total 1,604 patients with type 1 diabetes, 1,047 (65.3%) 
died.	Median	survival	time	increased	significantly	from	3.6	years	(95%	CI	2.50-
4.70) in the 1980–1984 cohort to 7.24 years (95% CI 5.74-8.74) in the 1995–1999 
cohort (Figure 1). In patients who started RRT during 2000–2005, median survival 
time was over eight years and therefore could not be precisely calculated because 
it was longer than the maximal follow-up time. Furthermore, median survival 
times	increased	significantly	in	all	age-groups.	From	1980–1984	to	2000–2005,	
absolute	risk	of	death	within	five	years	from	RRT	start	decreased	from	58%	to	
38% (Figure 2), with the unadjusted relative risk (RR) of death diminishing to 55% 
in patients during 2000–2005 compared to the cohort of 1980–1984 (Table 4). 
In age subgroups, the corresponding risk ratios were even lower (0.31-0.38; the 
lowest in patients under 35 years and the highest in patients 55 years or above), 
indicating the confounding effect of age. In all cohorts combined, the risk of death 
increased by 4.2% (95% CI 3.4-4.7) per year of age at start of RRT.
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Figure 1  Survival of patients with type 1 diabetes entering chronic renal replacement therapy 
(RRT) according to start period of RRT. 
(Reproduced and adapted from Mikko Haapio et al. Survival of Patients with Type 1 Diabetes Receiving Renal 
Replacement Therapy in 1980–2007. Diabetes Care (2010) 33 (8): 1718-1723. By permission of The American 
Diabetes Association.)
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Figure 2  Absolute risk (%) of death within five years from start of chronic renal replacement 
therapy (RRT) according to start period of RRT, in patients with type 1 diabetes (blue bars) 
and patients with glomerulonephritis (orange bars).
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Table 4  Relative risk (RR) of death in patients with type 1 diabetes according to start period 
of chronic renal replacement therapy (RRT).
RRT start 
period
Unadjusted RR 
(95% CI)
Adjusted1 RR 
(95% CI)
Adjusted2 RR 
(95% CI)
1980–19843 1 1 1
1985–1989 0.87 (0.72-1.06) 0.72 (0.59-0.87) 0.64 (0.52-0.77)
1990–1994 0.70 (0.58-0.85) 0.53 (0.44-0.65) 0.44 (0.36-0.54)
1995–1999 0.66 (0.54-0.81) 0.43 (0.35-0.52) 0.33 (0.27-0.41)
2000–2005 0.55 (0.44-0.68) 0.33 (0.26-0.41) 0.23 (0.19-0.29)
CI, confidence interval 
1Adjusted for age at RRT start and for gender
2Adjusted for age at RRT start and for gender, initial mode of dialysis, and having or not 
having received a kidney transplant within two years of RRT start
3Reference group
(Reproduced and adapted from Mikko Haapio et al. Survival of Patients with Type 1 Diabetes Receiving Renal 
Replacement Therapy in 1980–2007. Diabetes Care (2010) 33 (8): 1718-1723. By permission of The American 
Diabetes Association.)
Of the 1,556 patients with glomerulonephritis, 823 (52.9%) died during follow-
up, and compared to patients with type 1 diabetes, their median survival time was 
significantly	longer,	but	showed	no	significant	increase;	the	five-year	risk	of	death	
in 1980–1984 was 29% (95% CI 0.23-0.35) and was still the same in 2000–2005 
(Figure 2). In unadjusted analysis and compared to the cohort of 1980–1984, the 
RR	of	death	in	the	2000–2005	cohort	was	non-significantly	 lower,	0.88	(95%	
CI 0.68-1.14) (Table 5).
Table 5  Relative risk (RR) of death in patients with glomerulonephritis according to start 
period of chronic renal replacement therapy (RRT).
RRT start 
period
Unadjusted RR 
(95% CI)
Adjusted1 RR 
(95% CI)
Adjusted2 RR 
(95% CI)
1980–19843 1 1 1
1985–1989 1.01 (0.82-1.25) 0.86 (0.69-1.06) 0.76 (0.61-0.94)
1990–1994 1.21 (0.98-1.50) 0.72 (0.58-0.90) 0.60 (0.48-0.75)
1995–1999 1.17 (0.93-1.46) 0.59 (0.47-0.74) 0.49 (0.38-0.62)
2000–2005 0.88 (0.68-1.14) 0.37 (0.28-0.49) 0.30 (0.23-0.40)
CI, confidence interval 
1Adjusted for age at RRT start and for gender
2Adjusted for age at RRT start and for gender, initial mode of dialysis, and having or not 
having received a kidney transplant within two years of RRT start
3Reference group
(Reproduced and adapted from Mikko Haapio et al. Survival of Patients with Type 1 Diabetes Receiving Renal 
Replacement Therapy in 1980–2007. Diabetes Care (2010) 33 (8): 1718-1723. By permission of The American 
Diabetes Association.)
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5.1.2 ADJUSTED SURVIVAL
When	adjusting	for	age	and	gender	in	survival	analyses,	an	even	more	significant	
improvement in survival was detectable in patients with type 1 diabetes. Compared 
to 1980–1984, patients starting RRT in 2000–2005 had a RR of death of only 
0.33 (Table 4). With further adjustment for initial mode of dialysis and whether 
a patient had received a kidney transplant within two years of RRT start, the 
corresponding RR fell to 0.23.
Similarly,	in	patients	with	glomerulonephritis,	a	significant	improvement	in	
prognosis occurred, with a RR of 0.30 in 2000–2005 compared to 1980–1984 
(Table 5).
5.1.3 COMPARISON OF SURVIVAL BETWEEN PATIENTS  
 WITH TYPE 1 DIABETES AND GLOMERULONEPHRITIS
To compare the magnitude of change detectable in survival of both patient groups, 
we performed interaction analysis between the patient groups and the RRT start 
period, with adjustment for age, gender, RRT mode, and kidney transplantation 
status at two years from RRT start. This revealed that the RR of death decreased 
more in patients with type 1 diabetes than in patients with glomerulonephritis 
(p=0.007). In 1980–1984, patients with type 1 diabetes had a 3.5-fold higher risk 
of death than did glomerulonephritis patients, and this risk had diminished to 
2.7-fold in the 2000–2005 cohort.
5.2 DECLINE IN GLOMERULAR FILTRATION RATE   
 DURING PRE-DIALYSIS PHASE AND SURVIVAL ON  
 CHRONIC RENAL REPLACEMENT THERAPY
5.2.1 FACTORS ASSOCIATED WITH RAPID eGFR DECLINE
Dividing the 319 patients into tertiles according to eGFR decline rate during the 
year preceding start of chronic RRT clearly separated the fastest decliners from 
the	two	slower	groups	(Figure	3).	Significant	differences	in	patient	characteristics	
emerged between the three eGFR decline groups, especially after separating the 
fastest decliners from the other groups. The fastest decliners were younger and 
had a lower serum albumin concentration (Table 6). In addition, frequency of 
males and type 1 diabetes were both clearly higher among the fast decliners, and 
nephrological follow-up had been shorter for them.
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Table 6  Characteristics of patient groups according to estimated glomerular filtration rate 
(eGFR) decline rate during the year before starting chronic renal replacement therapy (RRT). 
Variables expressed as median (interquartile range) unless otherwise stated.
eGFR decline rate tertiles  
(mL/min/1.73 m2 per year) All 
(n=319) p-valueSlowest 
(n=105)
Intermediate 
(n=107)
Fastest 
(n=107)
At RRT start
    Age, years 64 (53-72)
56 
(46-70)
54 
(41-65)
60 
(47-69) < 0.001
    Males, % 49 63 70 61 0.005
    Body mass index, kg/m2 26 (23-30)
25 
(22-27)
24 
(22-27)
25 
(22-28) 0.028
    Blood hemoglobin, g/L 108 (97-120)
105 
(94-118)
102 
(92-111)
104 
(94-117) 0.039
    Serum albumin, g/L 35 (32-38)
34 
(30-38)
30 
(26-35)
34 
(29-37) < 0.001
    Nephrological follow-up,
    months
47.5 
(20.2-92.3)
49.9 
(16.2-92.7)
16.3 
(7.6-33.6)
32.7 
(11.2-81.2) < 0.001
    Residual renal function, 
    diuresis, L/day
1.8 
(1.2-2.2)
1.8 
(1.2-2.4)
1.6 
(1.0-2.2)
1.7 
(1.1-2.2) 0.332
    eGFR, mL/min/1.73 m2 7.8 (6.2-10.0)
6.7 
(5.3-8.2)
6.8 
(5.2-8.5)
7.1 
(5.6-8.8) 0.005
eGFR approx. 3 months 
prior to RRT start, 
mL/min/1.73 m2
8.1 
(7.0-10.1)
8.8 
(7.3-11.1)
11.5 
(8.6-16.5)
9.2 
(7.3-11.9) < 0.001
eGFR approx. 12 months 
prior to RRT start, 
mL/min/1.73 m2
9.3 
(7.6-12.1)
11.6 
(10.5-14.2)
19.8 
(15.8-29.5)
13.3 
(9.7-18.7) < 0.001
ESRD diagnosis, % 0.001
    Glomerulonephritis 15 12 13 14 (43)
    Polycystic degeneration 15 17 4 12 (38)
    Type 1 diabetes 11 27 32 24 (75)
    Type 2 diabetes 16 12 18 15 (49)
    Pyelonephritis 12 5 2 6 (20)
    Amyloidosis 6 9 8 8 (25)
    Other or undefined 24 18 23 22 (69)
ESRD, end-stage renal disease
eGFR decline rate tertiles (mL/min/1.73 m2/year): slowest = less than 3.4, intermediate = 
3.4-8.5, fastest = over 8.5.
(Reproduced and adapted from Mikko Haapio et al. Decline in Glomerular Filtration Rate During Pre-dialysis 
Phase and Survival on Chronic Renal Replacement Therapy. Nephrology Dialysis Transplantation (2012) 27 
(3): 1157-1163. By permission of Oxford University Press on behalf of ERA-EDTA.)
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Figure 3  Estimated glomerular filtration rate (eGFR) values at the three measurement points 
in Study II. Patients divided according to the tertiles of eGFR decline rate (x-axis) during 
the year preceding start of chronic renal replacement therapy; eGFR (y-axis) expressed as 
ml/min/1.73 m2.
Among the patients with a slower eGFR decline, pyelonephritis and polycystic 
kidney degeneration were more frequent than in the fastest eGFR decliners. Of 
note, frequency of kidney transplantation did not differ between the eGFR decline 
tertiles. In multivariable analysis, use of angiotensin-converting enzyme inhibitor 
or angiotensin receptor blocker and male gender (in this order of statistical 
significance)	remained	independent	predictors	of	rapid	eGFR	decline.
5.2.2 COMORBIDITIES AND eGFR DECLINE RATE
When	 comparing	 the	 three	 groups	 and	 without	 adjustment,	 no	 significant	
differences in the distribution of non-renal diagnoses nor the number of 
comorbidities were detectable (Table 7). With adjustment for age, however, angina 
pectoris and left ventricular hypertrophy were more frequent among the patients 
with the fastest eGFR decline. Having one or more comorbidities was also more 
common in that group.
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Table 7  Comorbidities of patients according to estimated glomerular filtration rate (eGFR) 
decline rate during the year before starting chronic renal replacement therapy. Variables 
expressed as percentage within eGFR tertile.
eGFR decline rate tertiles 
(mL/min/1.73 m2 per year) All 
(n=319) p-valueSlowest 
(n=105)
Intermediate 
(n=107)
Fastest 
(n=107)
Comorbidity, diagnosis –
    Angina pectoris 25 34 31 30 (94) 0.337
    Myocardial infarction 15 12 18 15 (47) 0.514
    Cerebral infarction 7 6 8 7 (22) 0.728
    Left ventricular 
    hypertrophy 33 46 42 41 (113) 0.162
    Cancer 6 3 6 5 (15) 0.507
Comorbidity, amount 0.529
    None 51 40 43 45 (143) –
    1 26 32 28 29 (91) –
    2 or more 23 28 29 27 (85) –
eGFR decline rate tertiles (mL/min/1.73 m2/year): slowest = less than 3.4, intermediate 
= 3.4-8.5, fastest = over 8.5.
(Reproduced and adapted from Mikko Haapio et al. Decline in Glomerular Filtration Rate During Pre-dialysis 
Phase and Survival on Chronic Renal Replacement Therapy. Nephrology Dialysis Transplantation (2012) 27 
(3): 1157-1163. By permission of Oxford University Press on behalf of ERA-EDTA.)
5.2.3 SURVIVAL ACCORDING TO eGFR SLOPE
Of the 319 patients, a total of 214 (67%) died during the 10 years of follow-up. 
The median survival time for the whole cohort was 5.6 (95% CI 4.2-7.0) years. 
Cause of death was cardiovascular in 44% and infection in 22% of all patients, 
with	no	significant	difference	between	eGFR	tertiles.
The	 risk	 of	 death	 did	 not	 significantly	 differ	 between	 patient	 groups	 in	
unadjusted analysis (Table 8). When adjusted for age and gender, however, the 
RR of death for the group with the fastest eGFR decline was 1.73 compared to the 
slowest eGFR decline group (Table 8 and Figure 4). With additional adjustment 
either	separately	or	in	combination	for	variables	that	were	significantly	differently	
distributed between the tertiles (body mass index, serum albumin, hemoglobin, 
angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, ESRD 
diagnosis, and comorbidities as a group, and length of nephrological follow-up), 
the risk of death in all cases diminished (Table 8).
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Table 8  Crude and adjusted relative risk (RR) of death according to estimated glomerular 
filtration rate (eGFR) decline rate during the year before starting chronic renal replacement 
therapy.
eGFR decline rate tertiles 
(mL/min/1.73 m2 per year) (n)
Unadjusted RR 
(95% CI)
Adjusteda RR 
(95% CI)
Adjustedb RR 
(95% CI)
Slowest (105) 1 (reference group)
1 
(reference group)
1 
(reference group)
Intermediate (107) 0.75 (0.54-1.04) 1.09 (0.77-1.52) 0.84 (0.57-1.25)
Fastest (107) 0.96 (0.69-1.32) 1.73 (1.23-2.44) 1.20 (0.79-1.80)
CI, confidence interval
eGFR decline rate tertiles (mL/min/1.73 m2/year): slowest = less than 3.4, intermediate = 
3.4-8.5, fastest = over 8.5.
aAdjusted for age at start of RRT and for gender.
bAdjusted for the 12 variables of the large Cox regression model: age at start of RRT, gender, 
ESRD diagnosis (compared to glomerulonephritis), comorbidities (all separately: angina 
pectoris, myocardial infarction, cerebral infarction, left ventricular hypertrophy, cancer), use 
of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, body mass index 
(per 5 kg/m2 increment), blood hemoglobin (per 10 g/L increment), and serum albumin (per 
5 g/L increment). 
Figure 4  Probability of survival according to tertile of estimated glomerular filtration rate 
(eGFR) decline rate during pre-dialysis phase. eGFR adjusted for age and gender and 
expressed in ml/min/1.73 m2/year. 
(Reproduced and adapted from Mikko Haapio et al. Decline in Glomerular Filtration Rate During Pre-dialysis 
Phase and Survival on Chronic Renal Replacement Therapy. Nephrology Dialysis Transplantation (2012) 27 
(3): 1157-1163. By permission of Oxford University Press on behalf of ERA-EDTA.)
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In order to further explore the factors associated with fast eGFR decline and 
higher risk of mortality, we constructed a large multivariable model comprising 
12 variables in addition to eGFR tertiles (Table 8, farthest right). Judged by data 
availability, we included 294 patients (92%) of the total cohort, of which 198 (67%) 
died during follow-up. In this model, age at start of RRT, the comorbidities of 
cancer and myocardial infarction, serum albumin, and ESRD diagnosis remained 
statistically	significant	predictors	of	survival.	Type	1	diabetes	and	amyloidosis	were	
associated with the worst survival of all ESRD diagnoses analyzed. Decline rate of 
eGFR	in	the	large	model	was	not	a	statistically	significant	predictor	of	mortality.
5.3 MODALITY OF CHRONIC RENAL REPLACEMENT  
 THERAPY AND SURVIVAL
5.3.1 FACTORS ASSOCIATED WITH DIALYSIS MODALITIES
Results	of	 the	primary	analysis	method,	 intention-to-treat,	 showed	significant	
differences in baseline characteristics between those patients who started chronic 
RRT with HD and those who started with PD (Table 9). The HD patients were on 
average older, with more commonly anemia and low serum albumin. Regarding 
ESRD diagnoses, HD patients were less likely to have glomerulonephritis or type 1 
diabetes, and more likely to have polycystic disease, type 2 diabetes, or amyloidosis.
A	significantly	 larger	proportion	of	PD	patients	were	placed	on	the	kidney	
transplant waitlist both at three months and at one year from start of chronic 
RRT,	and	underwent	significantly	more	kidney	transplantations	within	two	years	
(Table 10).
In terms of comorbid illnesses, those patients starting on HD modalities were 
much more likely to have ischemic heart disease, left ventricular hypertrophy, heart 
failure, peripheral vascular disease, stroke, or cancer than were those starting on 
PD modalities, and furthermore, HD patients were more likely to present with 
four or more comorbidities, whereas PD patients were more likely to be free of 
major comorbidities (Table 11).
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Table 9  Patient characteristics according to dialysis modality group in Study III.
HD PD p-value
Number 3,246 1,217 –
Males, % 63.6 64.3 0.217
Age at RRT start, years median 
(IQR) 64.4 (53.9-73.2) 55.2 (43.1-66.7) < 0.001
Body mass index, median (IQR) 26 (23-30) 25 (22-28) < 0.001
eGFR (MDRD) at RRT start, 
ml/min/1.73 m2 median (IQR) 8.5 (6.5-11.2) 8.8 (6.7-11.2) 0.195
Hemoglobin, g/L, median (IQR) 105 (95-116) 114 (104-123) < 0.001
Albumin, g/L, median (IQR) 33 (28-37) 35 (30-38) < 0.001
ESRD dg, % within modality group
    Glomerulonephritis 12.7 17.2 < 0.001
    Polycystic disease 10.2 6.0 < 0.001
    Type 1 diabetes 10.1 29.5 < 0.001
    Type 2 diabetes 22.7 14.2 < 0.001
    Pyelonephritis 3.6 4.0 0.540
    Amyloidosis 5.0 2.4 < 0.001
    Nephrosclerosis 5.9 5.3 0.445
    Other 14.1 10.4 0.001
    Unknown 15.7 11.1 < 0.001
HD, hemodialysis; PD, peritoneal dialysis; RRT, renal replacement therapy; IQR, interquartile 
range; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal 
Disease formula; ESRD, end-stage renal disease
(Reproduced and adapted from Mikko Haapio et al. Modality of Chronic Renal Replacement Therapy and 
Survival – A Complete Cohort from Finland, 2000–2009. Nephrology Dialysis Transplantation (2013) 28 (12): 
3072-3081. By permission of Oxford University Press on behalf of ERA-EDTA.)
Table 10  Kidney transplant waitlist status and transplantations according to dialysis modality 
group (percent within modality group).
HD PD p-value
On transplant waitlist at three months from RRT start 3.9 13.6 < 0.001
On transplant waitlist by one year from RRT start 22.8 50.8 < 0.001
Kidney transplantation within two years from RRT start 13.7 28.1 < 0.001
HD, hemodialysis; PD, peritoneal dialysis; RRT, renal replacement therapy
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Table 11  Type and number of comorbidities according to dialysis modality group (percent 
within group).
HD PD p-value
Type of comorbidity
    Angina pectoris 23.2 14.2 < 0.001
    Myocardial infarction 16.6 13.2 0.006
    Left ventricular hypertrophy 35.7 29.8 0.001
    Heart failure 11.9 7.3 < 0.001
    Peripheral vascular disease 14.4 8.2 < 0.001
    Peripheral vascular disease with surgery 8.5 4.1 < 0.001
    Peripheral vascular disease with limb  
    amputation 5.0 3.3 0.018
    Stroke 12.3 9.7 0.022
    Cancer 12.8 5.8 < 0.001
Number of comorbidities < 0.001
    None 46.3 56.0 < 0.001
    One 24.3 23.7 0.671
    Two 12.1 10.4 0.115
    Three 8.3 5.3 0.001
    Four or more 8.9 4.5 < 0.001
HD, hemodialysis; PD, peritoneal dialysis
(Reproduced and adapted from Mikko Haapio et al. Modality of Chronic Renal Replacement Therapy and 
Survival – A Complete Cohort from Finland, 2000–2009. Nephrology Dialysis Transplantation (2013) 28 (12): 
3072-3081. By permission of Oxford University Press on behalf of ERA-EDTA.)
5.3.2 DIALYSIS MODALITY AND SURVIVAL
Of the total 4,463, 1,887 (42%) died during the 10 years of follow-up, with a 
median	survival	of	5.2	(95%	CI	4.9-5.6)	years.	A	significant	survival	advantage	
on PD emerged (median 8.1 [95% CI 6.8-9.4] years on PD vs. 4.7 [95% CI 4.5-
5.0] years on HD).
5.3.2.1  Intention-to-treat analysis
The primary analysis method was intention-to-treat. Unadjusted analysis showed 
a	significantly	lower	risk	of	death	for	those	patients	who	started	on	PD	(RR	0.65,	
95% CI 0.58-0.73, p<0.001) (Table 12). However, after adjusting for age and 
gender,	no	significant	survival	difference	emerged.	To	perform	comprehensive	
control of confounders, we used a large multivariable model with 26 variables. 
Of all the 3,939 patients in the model (88% of the total cohort), 1,619 (41%) 
died during follow-up. Contradicting the unadjusted model, this model showed 
no	 statistically	 significant	difference	 in	RR	of	death	between	 the	patients	 on	
the two dialysis modalities. Censoring or not censoring at the time of kidney 
transplantation did not alter these results, nor did adjustment for transplantation 
as a time-dependent variable (data not shown), which resulted in a very similar 
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outcome as with censoring at transplantation. Figure 5 portrays unadjusted and 
multi-adjusted survival probabilities of the intention-to-treat analysis (Figure 5).
We tested the proportional hazards assumption for HD versus PD and found 
that it was not violated in the Cox model (p=0.254).
Table 12  Relative risk (RR) of death with the primary and the secondary analysis techniques 
and according to the chronic dialysis modality group.
Unadjusted 
RR (95% CI)
Adjusteda 
RR (95% CI)
Adjustedb 
RR (95% CI)
Adjustedc 
RR (95% CI)
Censored
at Txb
Intention-to-treat 
analysis (n)
HDd
(3246) 1 1 1 1 1
PD
(1217)
0.65 
(0.58-0.73)e
0.90 
(0.80-1.01) 
1.07 
(0.94-1.22)
1.04 
(0.91-1.19)
1.09 
(0.95-1.25)
As-treated 
analysis (n)
HD permanentlyd
(3064) 1 1 1 1 1
PD permanently
(885)
0.62 
(0.54-0.70)e
0.95 
(0.83-1.09) 
1.17 
(1.00-1.37)f
1.12 
(0.96-1.31)
1.33 
(1.12-1.56)e
HD to PD
(182)
0.99 
(0.79-1.23)
1.32 
(1.06-1.65)f
1.23 
(0.97-1.57)
1.25 
(0.98-1.59)
1.11 
(0.87-1.42)
PD to HD
(332)
0.73 
(0.61-0.87)e
0.85 
(0.71-1.02)
0.96 
(0.78-1.17)
0.96 
(0.79-1.18)
0.85 
(0.69-1.04)
CI, confidence interval; Tx, kidney transplantation; HD, hemodialysis; PD, peritoneal dialysis
aAdjusted for age at start of RRT and for gender.
bAdjusted for the 26 variables of the large Cox regression model: age at the start of RRT, 
gender, transplant waitlist status at three months from RRT start, body mass index, end-
stage renal disease diagnosis, RRT start year, eGFR at RRT start, serum urea, serum 
albumin, blood hemoglobin, systolic blood pressure, diastolic blood pressure, use of vitamin 
D, use of erythropoietin, and comorbidities (angina pectoris, myocardial infarction, cardiac 
left ventricular hypertrophy, heart failure, peripheral vascular disease, surgery for peripheral 
vascular disease, limb amputation for peripheral vascular disease, stroke and cancer), 
medication or diet treatment for hyperlipidemia, medication for hypertension, and cigarette-
smoking status.
cAdjusted as previously, but omitting the variable “transplant waitlist status at three months 
from RRT start”.
dReference group
ep≤0.001
fp<0.05
(Reproduced and adapted from Mikko Haapio et al. Modality of Chronic Renal Replacement Therapy and 
Survival – A Complete Cohort from Finland, 2000–2009. Nephrology Dialysis Transplantation (2013) 28 (12): 
3072-3081. By permission of Oxford University Press on behalf of ERA-EDTA.)
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Figure 5  Probability of survival in study groups with the primary analysis method (intention-
to-treat). Left: unadjusted survival probabilities. Right: multi-adjusted survival probabilities.
(Reproduced and adapted from Mikko Haapio et al. Modality of Chronic Renal Replacement Therapy and 
Survival – A Complete Cohort from Finland, 2000–2009. Nephrology Dialysis Transplantation (2013) 28 (12): 
3072-3081. By permission of Oxford University Press on behalf of ERA-EDTA.)
5.3.2.2  As-treated analysis
We used as-treated analysis as a secondary approach. In line with the results of 
the primary analyses, it also indicated the lowest unadjusted risk of death for 
patients who started with PD (Table 12). Again similarly as for primary analyses, 
adding adjustment for age and for gender reduced survival differences mostly to a 
nonsignificant	level.	However,	employing	the	large	multivariable	model	resulted	
in a 17% (p=0.047) higher mortality risk for patients exclusively treated with PD, 
and	even	further	increased	RR	(33%,	p≤0.001)	when	censoring	at	transplantation	
in the same patient group. Figure 6 illustrates both unadjusted and fully adjusted 
survival probabilities of the as-treated analysis (Figure 6).
Between those exclusively either on PD or on HD, no nonproportionality in the 
hazards appeared observable over time (p=0.887), but the hazards of those who 
switched from PD to HD or from HD to PD were not proportional to the hazards 
of those who were exclusively treated by HD (p=0.003 and p=0.005, respectively).
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Figure 6  Probability of survival in study groups by the secondary analysis method (as-
treated). Left: unadjusted survival probabilities. Right: multi-adjusted survival probabilities.
(Reproduced and adapted from Mikko Haapio et al. Modality of Chronic Renal Replacement Therapy and 
Survival – A Complete Cohort from Finland, 2000–2009. Nephrology Dialysis Transplantation (2013) 28 (12): 
3072-3081. By permission of Oxford University Press on behalf of ERA-EDTA.)
5.3.2.3  Subgroup analyses
To investigate whether the association between dialysis modality and survival 
differed between patient subgroups, we assessed interactions between treatment 
modalities and other explanatory variables; employing our multivariable model, 
we	found	no	significant	interactions.	Of	note,	no	interaction	occurred	between	
treatment modality and time spent on RRT (p=0.857). A tendency arose towards 
lower mortality in PD patients under age 45 and higher mortality in PD patients 
over age 75 compared to those of HD patients. PD patients with amyloidosis also 
showed a tendency toward higher mortality.
5.4 ONE- AND TWO-YEAR MORTALITY PREDICTION  
 FOR PATIENTS STARTING CHRONIC DIALYSIS
The two patient cohorts under investigation, the training and validation groups, 
differed	significantly	with	 respect	 to	patient	age	at	RRT	start	and	body	mass	
index, both of which were higher in the validation group. The validation group 
included more males, and more frequently the comorbidities angina pectoris, left 
ventricular hypertrophy, and cancer. A shift also occurred in the distribution of 
ESRD diagnoses toward fewer cases of pyelonephritis and amyloidosis and more 
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cases of nephrosclerosis from the older training group to the newer validation 
group.
A	clear	and	somewhat	unexpected	finding	was	the	significantly	lower	mortality	
rate of the validation group (Table 13).
Table 13  Mortality according to patient group in Study IV.
Training group (n=4,335) Validation group (n=1,768)
During one year During two years During one year(for 1,768)
During two years
(for 1,341)
Mortality, 
all patients, 
n (%)
597 (13.8) 1,080 (24.9) 197 (11.1) 283 (21.2)
5.4.1 PREDICTORS OF MORTALITY
We	first	tested	the	effect	on	death	risk	of	32	variables.	Including	all	the	variables	
in the logistic regression model resulted in 15 (one-year model) and 13 (two-year 
model) variables with p-values less than 0.05. We then compared the predictive 
performance	of	these	variables	in	several	combinations	and	finally	chose,	based	
on	results	from	calibration	and	discrimination,	seven	variables	to	the	final	one-
year	model	and	six	variables	to	the	final	two-year	model.	In	the	logistic	regression	
model,	all	of	 these	variables	were	highly	significant	 (p-value	 less	 than	0.001)	
(Table 14).
We	found	three	significant	first-degree	 interactions	 in	 the	one-year	model:	
between ESRD diagnosis and age at start of RRT, between serum albumin and 
age at start of RRT, and between ESRD diagnosis and heart failure, and one 
interaction in the two-year model: between ESRD diagnosis and heart failure.
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Table 14  Variables of the final mortality prediction models (with multivariable odds ratios 
and 95% confidence intervals).
Variables of the models One-year model Two-year model 
Age at RRT start, years 1.05 (1.04-1.06) 1.06 (1.05-1.06)
ESRD diagnosis – –
    Glomerulonephritis 1 (reference) 1 (reference)
    Polycystic disease 0.56 (0.28-1.11) 0.73 (0.46-1.17)
    Type 1 diabetes 2.16 (1.37-3.39) 2.81 (1.98-3.99)
    Type 2 diabetes 1.63 (1.13-2.36) 2.17 (1.62-2.90)
    Pyelonephritis 1.14 (0.60-2.19) 0.79 (0.46-1.38)
    Amyloidosis 3.10 (1.98-4.87) 3.72 (2.54-5.43)
    Nephrosclerosis 1.48 (0.91-2.40) 1.62 (1.10-2.40)
    Other 2.38 (1.63-3.49) 2.32 (1.70-3.17)
    Unknown 1.49 (1.00-2.20) 1.51 (1.10-2.07)
Serum albumin, g/L 0.96 (0.95-0.97) 0.96 (0.94-0.97)
Serum C-reactive protein, log 1.16 (1.07-1.24) 1.11 (1.05-1.18)
Heart failure 2.10 (1.65-2.69) 2.48 (1.98-3.10)
Serum phosphorus, mmol/L – –
    less than 1.53 1 (reference) –
    1.53 - < 2.0 0.75 (0.59-0.97) –
    2.0 or higher 1.15 (0.92-1.45) –
Peripheral vascular disease 1.66 (1.30-2.11) –
Peripheral vascular disease with 
limb amputation – 1.90 (1.36-2.65)
RRT, renal replacement therapy; ESRD, end-stage renal disease
5.4.2 VALIDATION OF THE MODELS
After	construction	of	the	two	final	models,	we	tested	their	predictive	performance	
in the validation group (Table 15). Compared to the training group and using the 
c-statistic (area under the curve, AUC), predictive ability was equal in the validation 
group in the one-year model and somewhat lower in the two-year model. To 
assess calibration of the models we categorized predicted probabilities of death 
into deciles and compared average predicted probabilities to mortality observed 
among the deciles (Figure 7). This resulted in less than optimal calibration in 
both models, with overestimation of death risks which was also indicated by the 
significant	p-values	in	the	Hosmer-Lemeshow	test.	Thus,	the	actual	mortality	in	
the validation group was lower than predicted by both the one- (Figure 7, left) 
and two-year (Figure 7, right) models.
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Table 15  Predictive performance of final models.
Training group (4,335) Validation group (1,768)
Model One-year Two-year One-year Two-year
n 4,335 4,335 1,418* 1,101*
AUC 0.768 0.764 0.769 0.740
Hosmer-Lemeshow test p-value 0.018 0.069 0.041 0.015
AUC, area under the curve
*those for whom data on all variables included were available
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Figure 7  Calibration of the one-year model (left) and two-year model (right). Average 
predicted probabilities of death (mean, blue bars) and observed mortality (proportion of 
patients who died, orange bars) according to decile of predicted probability of death (y-axis).
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6 DISCUSSION
6.1 FACTORS ASSOCIATED WITH SURVIVAL  
 OF PATIENTS ON CHRONIC RRT
6.1.1 PATIENTS WITH TYPE 1 DIABETES ON CHRONIC RRT   
 AND SURVIVAL
In Study I, we showed that survival of patients with type 1 diabetes receiving RRT 
has	significantly	improved.	For	patients	beginning	RRT	in	2000–2005,	risk	of	
death was 77% lower than for those entering RRT during 1980–1984. This study 
to	our	knowledge	was	the	first	to	observe	improvement	in	prognosis	of	patients	
with type 1 diabetes on chronic RRT with a follow-up lasting up to 28 years.
Our observations are in concordance with those of Sørensen and colleagues, 
who found improved overall survival of patients with diabetes (type 1 and 2 
combined)	by	14	to	18%	between	each	five-year	period	and	the	one	following	in	
1990–2005	(21).	Our	findings	are	also	in	line	with	the	observations	of	van	Dijk	
and colleagues in their European study including 10 countries. Their patients with 
type 1 diabetes were increasingly older at RRT start over the period 1991–1999 
(20). Albeit having had a modest (adjusted) two-year mortality reduction, their 
five-year	crude	survival	was	only	24%	for	those	having	no	a	kidney	transplant.	
Mortality reduction was more pronounced in those with a transplant, with 79% 
survival	at	five	years.
In contrast to our results, a registry study by Villar and colleagues from 
Australia / New Zealand showed no progress in survival estimate during 1991–
2005, even for those patients with type 1 diabetes with a kidney transplant (22). 
No obvious explanation existed for the dissimilarity with our results, but it may 
be linked to the much lower incidence of RRT resulting from type 1 diabetes in 
Australia / New Zealand.
Our observation includes several important aspects. First, a continuous and 
progressive increase has occurred in median survival time of patients with type 
1 diabetes on RRT, exceeding eight years for those entering RRT in 2000–2005. 
Second, the probability of survival on RRT has increased in all age-groups. 
Third, this improvement in survival has taken place despite the increasing age 
of patients starting RRT and the decreasing proportion of patients with kidney 
transplantation. Fourth, the survival prognosis of patients with type 1 diabetes 
has	improved	significantly	more	than	that	of	patients	with	glomerulonephritis.
It should also be noted that many favorable processes related to management 
of type 1 diabetes and chronic RRT have developed during recent decades. 
Treatment of type 1 diabetes has made many remarkable leaps forward since 
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the 1970s. Improved insulin regimens and equipment enabling more intensive 
blood glucose monitoring have been crucial in making treatment of type 1 diabetes 
easier and safer. In addition, many efforts to better manage chronic dialysis 
therapy,	 in	 terms	of	quality,	dose,	and	flexibility	 in	delivery,	have	succeeded.	
Examples	have	been	modern	synthetic	high-flux	hemodialyzers	with	better	toxin	
clearance	and	biocompatibility	as	well	as	use	of	ultrapure	fluid	in	on-line	HDF	
(108, 162). Similarly, reducing the symptoms and the consequences of uremia 
and	enhancing	patient	autonomy	are	PD	fluids	with	better	biocompatibility	and	
maximized	ultrafiltration,	and	overnight	automated	PD	(115,	119).	All	this	progress	
may also have contributed to better patient survival, but such evidence is still 
inadequate (51, 163-165).
Patients with type 1 diabetes live longer on chronic RRT. Clear proof is that 
despite a declining relative incidence of patients with type 1 diabetes entering 
chronic RRT, their proportion of all ESRD patients has remained constant (1). As 
our study results indicate, this may in part result from developments in diabetes 
care, because in the reference cohort (glomerulonephritis patients), survival 
improvement was less. It is also possible that management of cardiovascular 
risk factors, the leading causes of death in patients with type 1 diabetes, may be 
better achieved in these patients. Importantly though, most of the improvement in 
prognosis of patients with type 1 diabetes seems attributable to progress in RRT.
6.1.2 PRE-DIALYSIS PHASE eGFR DECLINE RATE AND SURVIVAL
In Study II, we investigated association of the eGFR decline pattern during one 
year before start of chronic RRT with subsequent survival on RRT. The rate of 
eGFR decline emerged as a factor that correlated with survival, not as a causal 
factor, but rather as a marker of a group of confounding factors. Our study was the 
first	published	in	the	field	to	investigate	eGFR	decline	and	the	resultant	survival	
on RRT.
Our results are in accordance with those of Rifkin and colleagues, Wu and 
colleagues and Chen and colleagues (95-97). These studies focused, however, 
either	on	mild	renal	 insufficiency	or	only	on	the	predialysis	phase	and	did	not	
reach to the start of dialysis. In the study by Rifkin and colleagues, an annual 
eGFR decline over 3 ml/min/1.73 m2 was associated with increased cardiovascular 
and all-cause mortality (95). Wu and colleagues found an association between 
intense predialysis patient education and a slower eGFR decline (slight increase 
vs. -1.3 ml/min/1.73 m2 during 12 months, test vs. control group, respectively), 
a lower risk for developing ESRD, and a lower risk of all-cause death (96). Chen 
and colleagues found late nephrology referral to correlate with faster eGFR decline 
(1.06 vs. 0.57 mL/min/1.73 m2/month) and higher mortality (97).
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In our study, eGFR decline more than 8.5 ml/min/1.73 m2 during the year 
preceding RRT start was associated with increased risk of death. We also found 
that patients with different causes of ESRD had different rates of eGFR decline. 
For instance, many of the patients with type 1 diabetes had a faster decline than 
did many of those with pyelonephritis or polycystic disease. Consequently, of all 
ESRD diagnoses in our study, type 1 diabetes and amyloidosis were associated 
with the worst survival, clearly worse than that in diagnoses of primary renal 
disease. The worse outcome associated with these ESRD causes is already known 
(22, 166). ESRD diagnosis, however, explains only a small part of the mortality 
effect of eGFR in our study, because when we adjusted for ESRD diagnosis, the 
association between decline and mortality weakened only slightly.
To clarify the potential causal as well as confounding factors behind survival 
rates in the three eGFR groups, we performed multivariable adjustment. The more 
comprehensive the adjustment, the weaker the association between eGFR decline 
and	survival	(finally	becoming	nonsignificant).	This	is	an	indication	of	multiple	
confounding factors correlating with both eGFR and mortality risk. Analyzing 
these factors one by one, we found especially ESRD diagnosis, serum albumin, 
and comorbidities to weaken the association between tertiles of eGFR decline 
and mortality. In our multivariable model, age at RRT start, cancer, myocardial 
infarction,	serum	albumin,	and	ESRD	diagnosis	emerged	as	statistically	significant	
predictors of mortality. These factors to some degree must lie behind the increased 
mortality risk indicated by the faster eGFR decline.
To further analyze the factors affecting survival on RRT we investigated the 
effect of kidney transplantation, causes of death, and length of nephrological 
follow-up. Interestingly, kidney transplantation was equally frequent between 
eGFR decline tertiles, as were causes of death. Nephrological follow-up, however, 
was shorter for the fast eGFR decliners, which could indicate a disadvantage 
from the short follow-up, but was most probably explainable by the more rapidly 
deteriorating renal function that brought the patients to nephrology referral later.
Low serum albumin was for us an independent predictor of rapid eGFR decline. 
Hypoalbuminemia is a well-known prognostic factor, portending adverse outcome 
in ESRD patients (58). It is generally a marker of poor nutritional status, chronic 
infection	or	inflammation,	and	sometimes	of	a	severe	nephrological	disease	with	
high proteinuria (167, 168). All these causes of hypoalbuminemia are also linked 
to worse outcome; logically low serum albumin could thus partly explain the faster 
eGFR decline associated with it among our study patients. Furthermore, although 
we had no data on frequency and magnitude of proteinuria, we may presume that 
proteinuria was present in many of the patients with low serum albumin. The 
association of proteinuria with worsening CKD and with cardiovascular adverse 
events in renal patients is established (169).
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Measurement of eGFR is widely spread in the follow-up of patients approaching 
the start of chronic RRT. However, based on present knowledge, knowing whether 
eGFR is high or low at RRT start does not reliably help predict survival of patients 
on RRT, nor do we know the optimal timing of RRT start with respect to eGFR and 
the ensuing survival on RRT. The formulae most commonly used for estimation of 
GFR, the Cockcroft-Gault, MDRD, and at present, CKD-EPI, are not optimal, with 
some investigators questioning their reliability (77, 170, 171). However, compared 
to serum creatinine measurement alone, the eGFR formulae considerably increase 
accuracy of renal function assessment in chronic and moderate or more severe 
insufficiency	(25).	The	eGFR	formulae	are	also	inexpensive	and	readily	available	
in a clinical setting. Thus, despite the well-recognized problems associated with 
serum creatinine-based estimation of GFR (e.g., abnormal muscle mass or poor 
nutritional status), these formulae are at present the most favored in follow-up 
of predialysis patients (77, 81). We saw it as important therefore to explore the 
predictive abilities of an eGFR formula for patients starting chronic RRT.
6.1.3 DIALYSIS MODALITY AND SURVIVAL
In Study III, we compared survival of patients on chronic RRT according to dialysis 
modality	on	day	91	after	RRT	start,	and	 found	a	significantly	 lower	mortality	
risk	for	PD	patients	than	for	HD	patients.	However,	this	finding	only	appeared	
in unadjusted analyses, because in our primary analyses (the intention-to-treat 
approach)	with	comprehensive	adjustment	for	confounding	factors,	no	significant	
mortality risk difference emerged. Interestingly, in our secondary analyses (the 
as-treated method) with full adjustment, those exclusively treated with PD had a 
17 to 33% higher risk of death than did those exclusively treated with HD.
The results of the primary and secondary analysis methods turned out to differ 
somewhat. We chose the intention-to-treat approach as our primary method for 
pragmatic reasons, since in reality it is infrequently known at the time of chronic 
RRT start whether a patient will later change dialysis modality. In addition, in 
the as-treated method, results would be subject to selection bias, because for a 
patient to be included in a group of modality changers, he/she must have lived 
until the modality switch. On the other hand, the secondary method (as-treated) 
can offer additional and versatile information not offered by the intention-to-treat 
method, and also enables direct comparison of those patients treated only with 
PD to those treated only with HD.
In observational studies like ours, comparing outcome (survival) can be 
complex because the groups compared against each other are dissimilar with 
regard to many variables affecting survival (61, 137). These factors are thus 
confounders, but with known confounders, the problem in comparisons can be 
solved by statistical adjustment. All this requires that reliable data are available. 
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Nevertheless, unknown confounders may still exist. Being on a transplant waitlist 
was clearly more frequent among PD patients and strongly correlated with survival, 
thus manifesting as a strong confounder. Whether a patient is waitlisted serves as 
a proxy of many favorable characteristics; survival analyses should therefore be 
adjusted for this factor. For this reason, we added adjustment for kidney transplant 
waitlist status at three months from RRT start at the head of all the other variables 
for which adjustment was done. Although waitlist status at one year could have 
been an even stronger confounder, and adjusting for it would probably have made 
our model even more comprehensive, we chose waitlist status at three months, as 
this was the time-point at which dialysis modalities were registered and because 
these data were already available at start of follow-up. Moreover, it could have 
carried with it a survivor effect.
As an alternative analysis, we performed censoring at time of kidney 
transplantation, assuming (in Kaplan-Meier and Cox regression) that the 
probability of survival of the censored transplanted patients would be same as 
that of those who remained in the follow-up. Censoring at transplantation could 
theoretically allow us to account for differences in transplantation rates between 
dialysis modalities. But, as we know that transplanted patients present with 
many favorable prognostic characteristics and that transplantation in itself may 
improve prognosis, this assumption of equal survival probability is not really 
true. With censoring at transplantation, no change was evident in our primary 
analyses, but instead we saw a further increased mortality risk for PD patients in 
the secondary analyses (Table 12). This evidently resulted from the higher number 
of transplanted patients belonging to the group treated only by PD. Additionally, 
instead of censoring at transplantation, we adjusted for transplantation as a 
time-dependent variable (data not shown), and produced results very similar 
as when censoring at transplantation. However, the same applies to both these 
actions: censoring at transplantation and adjusting for transplantation as applies 
to adjusting for transplant waitlist status at one year; those data did not exist at 
the start of follow-up, and we therefore decided to use waitlist status at RRT start.
In many studies, investigators explored interactions between survival during 
different dialysis modalities and between patient subgroups. Some results have 
been	conflicting.	 In	some	studies,	PD	has	been	associated	with	better	survival	
in younger patients without comorbidities (39, 40) and with worse outcome in 
older diabetic patients (41, 47). Conversely, no difference appeared in two registry 
studies, one comparing survival of non-diabetic CAPD and HD patients (46), and 
the other comparing initial dialysis modalities of non-diabetic waitlisted patients 
(56).	Our	study,	however,	showed	no	significant	 interactions	between	dialysis	
modality and age-group or comorbidities with respect to survival. It did, however, 
show a tendency towards better survival in young and worse survival in old patients 
on	PD,	a	finding	which	might	have	been	significant	had	we	had	more	patients.
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To date, only one study has used randomized patient selection in comparing 
dialysis modalities with respect to survival (156). Regrettably, that study was 
prematurely halted because of its low inclusion rate, and thus did not reach 
sufficient	 statistical	 power.	 Although	 our	 study	 was	 observational	 and	 not	
randomized, we were able to use exceptionally comprehensive data in terms of 
national and patient coverage as well as information on potential confounders. 
Moreover, when deciding which dialysis modality is best for a given patient, all 
factors affecting it from the patient’s social and work status and physical and 
cognitive condition to the variety of nephrological resources, it seems that no large 
randomized	study	in	the	field	is	feasible.	Therefore,	well-conducted	observational	
studies, which hopefully provide relevant and useful information for management 
of	ESRD	populations,	are	justified.
6.1.4 PREDICTIVE MODELS FOR SURVIVAL ESTIMATION
In Study IV, we developed two mortality prediction algorithms for one- and two-
year mortality estimation for patients starting chronic dialysis.
Life-long treatment, chronic RRT, is strenuous and demanding not only for 
the individual patient but also for the health-care system. Models for estimation 
of mortality risk may serve both nephrologists and their ESRD patients, as well as 
the	nephrological	health-care	system	as	a	whole.	First,	a	baseline	risk-stratification	
could help to identify patients at increased risk, enabling possible preventive 
measures. In outpatient management of patients who gradually approach the start 
of	chronic	RRT,	such	identification	could	possibly	sharpen	individualized	patient	
care and hopefully delay the start of chronic RRT. Second, prognostic models 
could give an overview beyond usual patient-level considerations in reaching 
the best treatment decisions on, for instance, level of treatment activity, choice 
of dialysis modality, and the choice to proceed to kidney transplantation or not. 
Arguably,	in	many	cases,	clinical	experience	and	expertise	will	suffice	for	a	rough	
estimation of mortality risk, but at the same time prognosis provided by models 
could	offer	the	patient	some	justification	for	decisions	concerning	his	treatment.	
Third, management of expanding ESRD populations will require rational use of 
limited nephrological resources, in which survival prediction models could help 
in	identifying	patients	who	will	benefit	the	most	from	nephrological	interventions.	
Fourth, in efforts to reach equal and fair sharing of limited resources, models 
could help in making critical comparisons between practice patterns and outcome 
of	patients	in	differing	nephrological	units.	Fifth,	to	be	able	to	compare	scientific	
work on varied ESRD populations, it is important to have reliable baseline risk 
estimation. Prediction models could assist in this, and also in selection of study 
populations.
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For these reasons, mortality prediction models have been developed for 
patients	entering	chronic	dialysis.	Our	models	focused	on	survival	during	the	first	
two years after patients entered dialysis. We used a separate, less recent cohort for 
construction of the models, and then validated the models with an external, more 
recent patient cohort. The models showed comparably good predictive ability, 
especially	for	the	first	year	on	RRT,	and	somewhat	weaker	ability	for	the	first	two	
years	on	RRT.	The	 latter	resulted	from	the	significantly	 lower	mortality	of	 the	
validation group, which distorted calibration of the models and overestimated risk 
of death. It is important, though, that we chose a more recent and external patient 
cohort	for	validation,	because	this	realistically	reflects	how	predictive	models	are	
applied: to future patients. In contrast to our study, in most (almost all) earlier 
studies, validation cohorts were randomly drawn from the entire study population 
(62-65, 67-70), resulting in more uniform testing and validation groups, and 
therefore also, in many cases, good discrimination ability. However, although 
our approach slightly reduced the accuracy of our models, we see it as necessary 
for reliable validation.
Many	 similarities	 also	 arise	 between	 other	 studies	 in	 the	 field	 and	 ours,	
for instance, outcome with respect to discrimination ability, and the statistical 
methods	used.	An	AUC	for	mortality	prediction	of	0.72	to	0.84	for	the	first	year	
on	RRT	and	0.67	to	0.75	for	the	first	two	years	on	RRT	has	been	common,	and	
an AUC of 0.75 has usually been considered reasonably good (64, 66-70, 159, 
160).	Our	results	match	well	with	these	findings	and	requirements.	The	statistical	
method mostly employed in survival studies aiming at building prognostication 
models has been multivariable logistic regression analysis, typically using 
stepwise selection of variables, and also in our study. Another similarity between 
other studies is data source, which usually has been a health-care registry or 
administrative database (60-70, 159), deriving information from incident ESRD 
populations (60, 61, 64, 66-69).
Our results may be lined up against others’ results also with regard to the 
era of patient inclusion and patient characteristics potentially affecting survival 
outcome. Our training cohort started RRT during 2000–2008 and was thus from 
approximately the same years as cohorts of other studies referenced here (64-70, 
159, 160). Our validation cohort, however, from the year 2009 onwards, is clearly 
the most contemporary one thus far, with our follow-up lasting until the end of 
2013. This may add reliability and credibility to our study results. Unexpectedly, 
mortality	had	significantly	decreased	in	our	newer	cohort,	although	many	patient	
characteristics had evolved to some degree in an unfavorable direction considering 
how these factors may affect survival. For instance, age at RRT start and proportion 
of males had increased, as well as numbers with cancer. Serum albumin was lower 
in the newer cohort, a factor known to worsen prognosis strongly. Patients of 
the validation group were also more anemic and had higher serum phosphorus, 
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although these differences seemed small judged by experience in clinical work. 
On the other hand, patients of the newer cohort had a higher body mass index 
and serum creatinine, both factors generally linked to improvement of prognosis. 
Of other patient-level factors present in studies worth mentioning are the quite 
similar ages at RRT start as well as the proportion of patients starting with PD 
treatment (64, 67, 68). AUCs for survival on RRT reached in those studies: 0.72-
0.78, have also been close to the ones we detected.
Although the performance of many prediction models has been comparatively 
good, these models have by no means been near to optimal. Many reasons lie 
behind the limited ability of models to perform exact prognostication. Especially 
important are the large numbers of patient- and treatment-related factors 
potentially affecting survival and thus probably confounding survival analyses. 
Many of these factors are known and can be accounted for in the analyses, but 
many times the factors are not precisely characterized, or at least their effect on 
survival is poorly known. Furthermore, many of these factors tend to change over 
time. For instance, current ESRD patients are older than in the past and present 
with more comorbidities, thus being at increased risk of death. On the other 
hand, advancements both in general health care and in nephrological treatment 
are likely to improve their prognosis. Prognostic models built on earlier data 
may thus not achieve equal performance in future. Moreover, models are likely 
to overestimate mortality risk in newer populations when real improvement in 
prognosis occurs, a fact which became apparent in our study.
6.2 LIMITATIONS AND STRENGTHS
As	to	limitations,	first,	due	to	the	population-specific	data	of	the	Finnish	Registry	
for Kidney Diseases, our results may not be directly applicable to other populations. 
For instance, Study I with its clearly improved survival in patients with type 1 
diabetes on chronic RRT might not be generalizable to other countries, because 
the incidence of type 1 diabetes is among the highest in the world in Finland, 
with much attention paid to treating these patients. Similarly, with the results of 
Study IV, because the mortality prediction models for ESRD patients were based 
on data of only Finnish patients, the models may not perform equally well for 
others than Finns.
Second is the question of whether to do censoring at a certain point of follow-
up. In survival studies of ESRD patients, kidney transplantation may be especially 
important. In Study I, the number of patients receiving a kidney transplant was 
lower among those with type 1 diabetes than for glomerulonephritis patients 
(45% vs. 50%), and thus, had we performed censoring at transplantation, this 
would have further worsened the survival estimate of glomerulonephritis patients 
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compared to diabetes patients. To account for this difference we adjusted for 
having	or	not	having	received	a	transplant	within	the	first	two	years	on	RRT	(Table	
4). In Study II, no difference appeared in the frequency of kidney transplantation 
between the eGFR decline tertiles; we therefore neither censored at the time 
of transplantation nor adjusted for it. In Study III, we chose to present results 
both with and without censoring at time of transplantation. As was obvious in 
that study, censoring at transplantation affected the results to favor HD over 
PD in survival comparisons (i.e., increasing RR of death in PD compared to 
HD) (Table 12), because substantially more PD patients received a transplant 
during the follow-up (Table 10). In addition, data on future transplantations were 
unavailable when follow-up was started. In the main analyses of Study III, we 
decided, instead, to adjust for waitlist status, which gives similar information 
about patient characteristics as transplantation does, but at an earlier stage. In 
that way, we attempted to ensure adjustment for the selective characteristics of 
future transplantation patients.
Third is the issue related to censoring at transplantation: whether to perform 
adjustment for transplantation. Although we know that those ESRD patients who 
later receive a kidney transplant often present with many favorable characteristics 
(such as higher serum albumin and fewer comorbidities) associated with 
increased survival, so that adjusting for them would be necessary, in Study III 
we decided to mimic reality and not adjust for factors of the future. In other 
words, factors, even those potentially confounding, if they appear only during 
follow-up (transplantation), we did not adjust for. Instead, we decided to adjust 
for transplant waitlist status at start of follow-up.
Fourth,	data	in	Study	I	on	diagnostic	kidney	biopsies	confirming	the	ESRD	
diagnosis to be diabetes were incomplete. This is a consequence of the long-
common practice of performing no kidney biopsies on patients with type 1 diabetes 
and CKD if they present with other microvascular complications considered to be 
caused by diabetes (especially retinopathy). In the control group (patients with 
glomerulonephritis),	the	percentage	of	biopsy	confirmations	increased	over	the	
years and reached 85% in the most recent group (1995–2005).
Fifth, in Study IV, due to a reasonably large amount of data lacking in the 
training group, we performed multiple imputation for missing data; this may 
have altered analysis results, but to avoid selection bias from excluding patients 
with missing data, we felt imputation was necessary and expected it to give more 
reliable study results (172). Importantly, in the validation group no missing data 
were imputed.
The Finnish Registry for Kidney Diseases is recognized for its exceptionally 
high-quality data, and furthermore, comprehensive nationwide coverage of 
ESRD patients and nephrological units. The data included in the registry come 
directly from dialysis units and nephrologists treating dialysis and transplantation 
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patients. The process of regularly performed data collection is well incorporated 
in the everyday practice of nephrological units.
When using data of the Registry, results are guaranteed to represent Finnish 
ESRD patients comprehensively. The Registry is estimated to cover 97 to 99% 
of all Finnish patients receiving chronic RRT since 1965. Therefore, even in 
observational studies investigators can have reliable data with only a very few 
patients excluded (those not consenting the use of their information in the Registry, 
and these patients are nearly nonexistent). Resulting from the complete coverage 
of Finnish nephrological units the studies are multi-centered, and due to the 
process of data collection, also prospective in setting.
Of the individual studies underlying this thesis, the particular strength of Study 
I was the complete Finnish cohort of patients with type 1 diabetes and the length of 
follow-up	that	stretched	to	28	years.	The	study	was	the	first	to	show	improvement	
in the prognosis of patients with type 1 diabetes on RRT, based on such a long 
observational period. Study II, although rather small, was at its time of publication 
the	first	in	the	field.	Study	III	may	be	recognized	for	its	unusually	comprehensive	
adjustments, giving the study results special reliability. In Study IV, data were 
prospectively collected without exclusion. Importantly, we used an external and 
newer validation group and so gave the models a realistic performance test that 
better mimicked everyday clinical situations.
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7 CONCLUSIONS
The ESRD population shows high morbidity and mortality. Severe renal 
insufficiency	requiring	 the	start	of	chronic	RRT	is	a	great	burden	not	only	on	
individual patients, but also on health-care systems as a whole. The prognosis 
of ESRD patients in general has not improved to the degree anticipated, and 
factors	behind	heightened	mortality	are	still	insufficiently	known.	Identification	
of factors associated with the increased risk of mortality in ESRD patients could 
reveal potential opportunities to improve survival. This thesis was targeted to 
investigate and identify factors related to prognosis of ESRD patients entering 
chronic	RRT.	The	main	findings	were:
Study I: The survival of patients with type 1 diabetes and ESRD has continuously 
and	significantly	improved	from	1980	onwards	in	Finland	despite	the	progressively	
higher age at the start of chronic RRT. Survival of patients with glomerulonephritis 
(the control group in Study I) has also improved, but to a lesser extent. The 
improved outcome of patients with type 1 diabetes may result from both improved 
dialysis treatment and progress in diabetes care, and emphasizes the importance 
of comprehensive management of diabetes and other cardiovascular risk factors 
even in patients on chronic RRT.
Study II: In age-adjusted survival analyses, the rapid decline in estimated 
GFR during the year preceding start of chronic RRT is a marker of increased 
mortality on RRT. However, the association appears to be non-causal and mainly 
explained by the confounding effect of ESRD diagnosis, low serum albumin, and 
other comorbidities.
Study III: Comparison of survival between various dialysis modalities is 
hindered by patient selection. Many patient characteristics related to survival 
differ considerably between dialysis modalities, and thus confound the analysis. 
When these characteristics, most importantly age and kidney transplant waitlist 
status,	are	taken	into	account	and	adjusted	for	in	survival	analyses,	no	significant	
overall difference in survival between HD and PD patients emerges. Furthermore, 
no	significant	survival	difference	appeared	between	subgroups	of	patients	in	either	
dialysis modality.
Study	IV:	We	identified	several	factors	that	are	independently	and	significantly	
associated with survival of ESRD patients on chronic RRT. Based on these factors, 
we developed one- and two-year mortality prediction models with comparatively 
good prognostication ability (AUC 0.77 to 0.74). Due to the convenient size of 
the models in terms of numbers of variables, they can easily be applied in clinical 
work, to help nephrologists do individualized treatment-planning, and also to 
offer ESRD patients insight into decisions concerning treatment.
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